Surveillance and Defense Mechanisms in Microbes by Osuna, Beatriz Adriana
UCSF
UC San Francisco Electronic Theses and Dissertations
Title
Surveillance and Defense Mechanisms in Microbes
Permalink
https://escholarship.org/uc/item/7vw6d526
Author
Osuna, Beatriz Adriana
Publication Date
2019
 
Peer reviewed|Thesis/dissertation
eScholarship.org Powered by the California Digital Library
University of California
  
 
 
 
by 
 
 
 
 
Submitted in partial satisfaction of the requirements for degree of 
 
 
in 
 
 
 
in the 
 
GRADUATE DIVISION 
of the 
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 
 
 
 
 
 
 
 
 
 
 
 
 
Approved: 
 
______________________________________________________________________________ 
       Chair 
 
 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
Committee Members 
Biochemistry and Molecular Biology
Beatriz Osuna
DISSERTATION
Surveillance and Defense Mechanisms in Microbes
DOCTOR OF PHILOSOPHY
Joseph Bondy-Denomy
David Morgan
Seemay Chou
Alexander Johnson
	 ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright 2019 
 
by 
 
Beatriz A. Osuna 
 
	 iii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dedicated to Ali and Samir  
 
  
	 iv 
ACKNOWLEDGEMENTS  
 
 When I embarked on this journey, I thought that science would pose the greatest 
challenges I’d ever encounter. Looking back, I’m proud to say that overcoming scientific 
challenges has actually been the most enjoyable and rewarding aspect of this journey. I am so 
grateful to be at this point now—a scientist through and through, confident that I can approach 
any scientific problem and enjoy the process of finding a solution. Much to my surprise, non-
science obstacles were actually the most difficult. Nonetheless, even the non-science problems 
I couldn’t troubleshoot helped me grow as a scientist and overall human. I’m beyond grateful to 
the incredible people that were there for me during this rollercoaster of an experience.  
 Thank you to my best friend, partner, and colleague: Jonathan Asfaha. I’m so lucky that 
we’ve gone through grad school together. You’ve always been my biggest source of support. 
You always see the best in me. You always enthusiastically talk through data and experiments 
with me. You always wholeheartedly and sincerely celebrate my wins and you always hype me 
up when I’m discouraged by the L’s. Thank you for everything—I can’t even begin to imagine 
what grad school would have been like without you.  
 Thank you to the mentors that changed my life and made me the scientist I am today: 
my eighth-grade math teacher, Samir Bolar, and my undergrad supervisor, Alison Frand. I can 
never thank you enough for genuinely investing in me and encouraging me to reach my 
potential. Thank you to my friends for all their love and support: Jairo Lopez, Paola Castro, 
Emma Powell, Terri Lee, and Nathan Gamarra. Thank you to the incredible women that have 
been influential friends and mentors, both scientifically and generally: Gabriela Monsalve, 
D’Anne Duncan, and Seemay Chou. Thank you to my little brother, Enrique Torres, for always 
having my back. Thank you to my SRTP students for inspiring me to be the best mentor and 
scientist I can be; and above all, for giving me the opportunity to feel like I made a difference in 
their scientific training and trajectories.    
	 v 
 Of course, thank you to the scientists that advised my thesis work: David Weinberg and 
Joseph Bondy-Denomy. David—thank you for teaching me biochemistry and for inspiring me to 
become a fearless scientist. I am grateful that I had the opportunity to learn from an exceptional 
RNA biochemist that I truly respect and admire. Joe—thank you for welcoming me into your lab, 
for teaching me phage biology, and for giving me the freedom to grow immensely as a scientist. 
I feel so fortunate that I had the opportunity to work with the incredibly talented and brilliant 
group of scientists that comprise the JBD lab (including you, of course!). The strong work ethic 
and passion for science that’s been cultivated in your lab never ceases to amaze me! 
 Thank you to David Morgan for being my advocate and mentor throughout the entirety of 
my thesis work. Thank you to Sandy Johnson for providing helpful scientific advice as part of my 
thesis committee. Thank you to the brilliant scientists that worked with me directly: Conor 
Howard, Shweta Karambelkar, Caroline Mahendra, and Samuel Kilcher. It was truly a pleasure 
collaborating with you and learning from all of you.   
 Thank you to my yoga teachers for keeping me sane during this final stretch of my PhD 
journey. Finally, thank you to my therapists Adam Frey and Colby Croft. Thank you for helping 
me learn so much about myself. Most of all, thank you for your kindness and support when I 
needed it most.  
	 vi 
PUBLISHED WORK  
 
Chapter 1 is adapted from:  
Osuna, B.A., Howard, C.J., Kc, S., Frost, A., and Weinberg, D.E. (2017). In vitro analysis of 
 RQC activities provides insights into the mechanism and function of CAT tailing.  
 ELife 6, e27949. DOI: 10.7554/eLife.27949  
 
Chapter 2 is adapted from:  
Osuna, B.A., Karambelkar, S., Mahendra, C., Christie, K.A., Garcia, B., Davidson, A.R., 
 Kleinstiver, B.P., Kilcher, S., and Bondy-Denomy, J. (2019). Listeria phages induce  
 Cas9 degradation to protect lysogenic genomes. BioRxiv 787200.  
 DOI: https://doi.org/10.1101/787200  
  
	 vii 
ABSTRACT 
SURVEILLANCE AND DEFENSE MECHANISMS IN MICROBES 
Beatriz A. Osuna 
 To survive the harsh conditions of their environment, microbes have evolved protection 
mechanisms that counteract the most lethal of threats: damage to essential biosynthetic 
machinery and infiltration by foreign invaders. Surveillance mechanisms monitor fundamental 
biosynthetic processes—including DNA replication, mRNA transcription, and protein 
translation—to ensure their accuracy and limit the accumulation of incorrectly synthesized 
macromolecules in the cell. Immunity mechanisms, on the other hand, prevent cellular 
infiltration by external invaders such as viruses. In the first half of this study, I investigated a 
surveillance pathway that detects ribosomes stalled during protein translation and marks the 
incomplete nascent proteins for degradation. In yeast, this pathway was known to involve 
Carboxy-terminal Alanine and Threonine (CAT) tailing: a non-canonical, mRNA-independent 
peptide synthesis mechanism. However, the mechanism of CAT tailing and its role in 
maintaining protein homeostasis was unknown. Here, I show that CAT tailing requires the 
catalytic activity of fragmented 60S ribosomes and charged tRNAs, but is otherwise distinct from 
canonical protein synthesis. Moreover, CAT tailing of the incomplete nascent protein exposes a 
lysine residue that is modified with ubiquitin, a tag for protein destruction. In the second half of 
this study, I investigated the bacterial CRISPR-Cas9 immune system in Listeria 
monocytogenes, which detects and destroys invading phage (virus) DNA. The phage protein, 
AcrIIA1, was known to inactivate CRISPR-Cas9 but its mechanism was uncharacterized. Here, I 
show that AcrIIA1 binds to Cas9 with high affinity via the catalytic HNH domain to induce Cas9 
degradation, thereby protecting the Listeria genome during lysogeny but not during lytic growth. 
AcrIIA1 also directly represses transcription of the anti-CRISPR locus and is therefore required 
for optimal phage replication. Finally, bacterial hosts have co-opted AcrIIA1 homologs that 
potentially act as “anti-anti-CRISPRs” by blocking the deployment of phage anti-CRISPRs.  
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ABSTRACT 
 Ribosomes can stall during translation due to defects in the mRNA template or 
translation machinery, leading to the production of incomplete proteins. The Ribosome-
associated Quality control Complex (RQC) engages stalled ribosomes and targets nascent 
polypeptides for proteasomal degradation. However, how each RQC component contributes to 
this process remains unclear. Here we demonstrate that key RQC activities—Ltn1p-dependent 
ubiquitination and Rqc2p-mediated Carboxy-terminal Alanine and Threonine (CAT) tail 
elongation—can be recapitulated in vitro with a yeast cell-free system. Using this approach, we 
determined that CAT tailing is mechanistically distinct from canonical translation, that Ltn1p-
mediated ubiquitination depends on the poorly characterized RQC component Rqc1p, and that 
the process of CAT tailing enables robust ubiquitination of the nascent polypeptide. These 
findings establish a novel system to study the RQC and provide a framework for understanding 
how RQC factors coordinate their activities to facilitate clearance of incompletely synthesized 
proteins.  
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INTRODUCTION 
 Eukaryotic cells contain several cotranslational quality-control pathways that limit the 
production of aberrant proteins and thereby maintain protein homeostasis. One such pathway is 
activated when a ribosome fails to complete translation, leading to the recruitment of specialized 
factors that disassemble the stalled ribosome and facilitate degradation of the nascent protein 
(Brandman and Hegde, 2016; Shoemaker and Green, 2012). A key effector of this process is 
the highly conserved Ribosome-associated Quality control Complex (RQC), which in budding 
yeast comprises the E3 ubiquitin ligase Ltn1p, the ATPase Cdc48p, and the poorly 
characterized proteins Rqc1p and Rqc2p (Brandman et al., 2012; Defenouillère et al., 2013; 
Verma et al., 2013)—the human homologs of which are Listerin, VCP/p97, TCF25, and NEMF, 
respectively. The stalled translation complex is first separated into subunits by ribosome splitting 
factors, allowing the small ribosomal subunit (40S) and mRNA to be released. The RQC then 
recognizes and assembles on the large ribosomal subunit (60S) that still contains a nascent 
polypeptide linked to a tRNA molecule (60S:peptidyl–tRNA). Ltn1p facilitates ubiquitination of 
the nascent chain while on the 60S subunit, marking the incompletely synthesized protein for 
proteasomal degradation (Bengtson and Joazeiro, 2010; Shao et al., 2013). Additionally, Rqc2p 
recruits charged tRNAs to the 60S subunit to direct elongation of the nascent protein with a 
Carboxy-terminal Alanine and Threonine extension, or CAT tail (Shen et al., 2015).  
Structural analysis of the yeast RQC, identification of the tRNA molecules that co-purify 
with the RQC, and biochemical characterization of failed nascent chains suggested that CAT 
tailing occurs on the 60S subunit by a unique mechanism that does not require an mRNA 
template or the 40S subunit (Shen et al., 2015). However, many questions about the 
mechanism of CAT-tail synthesis and the consequences of elongating nascent polypeptides 
with CAT tails remain unanswered. Recent studies have suggested that one function of CAT 
tails is to facilitate aggregation of nascent polypeptides that fail to be ubiquitinated by Ltn1p (due 
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to either disruptions in LTN1 or the absence of a suitable ubiquitin acceptor). CAT tail-driven 
aggregation may limit the otherwise toxic effects of incomplete translation products 
accumulating in the cytoplasm (Choe et al., 2016; Defenouillère et al., 2016; Yonashiro et al., 
2016). However, our understanding of the functions of CAT tails in the context of an intact RQC 
or of the process of CAT tailing itself remains incomplete. 
 Previous studies have analyzed the RQC in vitro by using cell-free translation systems 
based on rabbit reticulocyte lysates (Shao et al., 2013) or Neurospora crassa extracts 
(Doamekpor et al., 2016). In the presence of a suitable mRNA substrate, both cell-free systems 
recapitulate Ltn1p-dependent ubiquitination and thereby provide valuable insight into the 
mechanism by which Ltn1p orthologs discriminate between elongating and stalled ribosomes 
(Shao et al., 2013) and the role of the N-terminal domain of Ltn1p in binding the 60S subunit 
(Doamekpor et al., 2016). However, neither system recapitulates Rcq2p-dependent CAT tailing, 
leaving important unanswered questions about how CAT tails are synthesized and whether the 
two principal activities of the RQC—ubiquitination by Ltn1p and CAT tailing by Rqc2p—are 
functionally related.  
 Although many studies have identified Rqc1p/TCF25 as a core component of the yeast 
and mammalian RQC required for nascent-chain degradation (Brandman et al., 2012; 
Defenouillère et al., 2013; Shao and Hegde, 2014), Rqc1p’s precise structural and functional 
roles in the complex remain unclear. Previous work in yeast suggested that Rqc1p acts after 
Ltn1p to promote nascent-chain degradation. This hypothesis emerged from two lines of 
evidence: The presence of polyubiquitinated proteins in purified RQC depends on Ltn1p (and to 
a lesser extent on Rqc2p) but not on Rqc1p or Cdc48p (Brandman and Hegde, 2016; Brandman 
et al., 2012); and recruitment of Cdc48p to the 60S subunit requires Rqc1p and nascent-chain 
ubiquitination (Defenouillère et al., 2013). However, these studies did not determine whether 
Rqc1p is necessary for ubiquitination of the nascent chain itself or whether recruitment of 
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Cdc48p requires a direct interaction with Rqc1p. Therefore, the mechanism by which Rqc1p 
promotes nascent-chain degradation in vivo has remained unclear.    
 In this study, we provide an in vitro characterization of the RQC in a budding-yeast 
extract that uniquely recapitulates ubiquitination by Ltn1p and CAT tailing by Rqc2p, providing 
new insights into RQC action in promoting degradation of stalled translation products.  
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RESULTS                     
A cell-free system that recapitulates Rqc2p-mediated nascent-chain elongation 
 Because CAT tails have thus far only been observed in S. cerevisiae (Choe et al., 2016; 
Defenouillère et al., 2016; Shen et al., 2015; Yonashiro et al., 2016), we used S. cerevisiae 
extracts to recapitulate Rqc2p-mediated elongation in vitro. Although S. cerevisiae has long 
been used for in vitro translation (Hussain and Leibowitz, 1986; Iizuka et al., 1994; Rojas-Duran 
and Gilbert, 2012; Tarun and Sachs, 1995), these reactions are notoriously inefficient. Further 
exacerbating this problem, we aimed to program these reactions with truncated mRNA 
substrates that trigger quality control, which are translated less efficiently because they lack 
poly(A) tails that normally enhance translation. Thus, we found it necessary to first establish an 
optimized protocol that could reproducibly generate translation products that were detectable by 
immunoblotting (see Materials and methods). Critical aspects of our protocol included: 1) lysing 
cells with a freezer mill under cryogenic conditions rather than by bead beating in the cold; 2) 
minimizing the number of lysis cycles; 3) removing small molecules by dialysis rather than by 
size-exclusion chromatography; and 4) programming translation reactions with an mRNA 
encoding a small protein (i.e., 23-kDa NanoLuc luciferase), which is translated more efficiently 
than an mRNA encoding a larger protein (e.g.,  62-kDa firefly luciferase). 
 To produce a substrate for the RQC, we used a truncated reporter mRNA that 
terminates with a sense codon (i.e., does not contain a stop codon, 3′–untranslated region (3′-
UTR), or poly(A) tail). This mRNA substrate has been shown previously to generate a 
ribosome–nascent chain complex stalled at the 3′ end of the message (Becker et al., 2011; 
Shao et al., 2013). Our reporter mRNA encodes a NanoLuc luciferase (NL) protein in which the 
seven native lysine residues have been mutated to arginine to avoid potential confounding 
effects of lysine ubiquitination. The protein also includes an N-terminal 3xHA tag (which is 
naturally devoid of lysines) to allow detection of translation products by immunoblotting.  
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Programming S. cerevisiae in vitro translation (ScIVT) reactions with a full-length control 
mRNA that contains a stop codon, 3′-UTR, and 50-nucleotide poly(A) tail resulted in the time-
dependent accumulation of a 23-kDa product corresponding to 3xHA-NL (Figure 1-1A, left). In 
contrast, ScIVT of a truncated mRNA initially produced a ~43-kDa mass-shifted product not 
observed in control reactions (Figure 1-1A, right), which we hypothesized corresponded to a 
peptidyl–tRNA intermediate. Remarkably, as the reaction proceeded we observed the 
disappearance of the initial ~43-kDa product and concomitant accumulation of smaller mass-
shifted products ranging from 23 kDa to 43 kDa (Figure 1-1A, right). These mass-shifted 
products were reminiscent of CAT-tailed species previously observed in vivo (Choe et al., 2016; 
Defenouillère et al., 2016; Shen et al., 2015; Yonashiro et al., 2016). 
To further characterize the mass-shifted species, we added a sequence encoding a TEV 
protease cleavage site (TCS) at the 3′ end of our mRNA substrate (Shen et al., 2015) and 
determined the susceptibility of the mass-shifted species to TEV protease and RNase. We 
reasoned that a nascent polypeptide with its C-terminus covalently linked to a tRNA molecule 
would be liberated by either TEV protease or RNase. In contrast, a nascent polypeptide 
containing an untemplated C-terminal amino-acid extension (e.g., a CAT tail) would be cleaved 
by TEV protease but not RNase, and a protein containing additional mass due to modifications 
anywhere except the C-terminus would be unaffected by either treatment. When treated with 
either RNase or TEV protease, the ~45-kDa intermediate observed at early time points was 
converted to a 25-kDa species, corresponding to the molecular weight of 3xHA-NL-TCS (Figure 
1-1B). Given that the average molecular weight of a tRNA is ~20 kDa, these results suggest that 
the ~45-kDa species contained a tRNA covalently linked to the C-terminus of 3xHA-NL-TCS 
(“peptidyl–tRNA”)—which has previously been characterized as an intermediate of the quality-
control pathway (Shao et al., 2013; Shoemaker et al., 2010; Tsuboi et al., 2012). In contrast, the 
heterogeneous collection of ~25–45-kDa products that accumulated at later time points were 
only affected by TEV protease, converting them to a discrete 25-kDa species (Figure 1-1B), as 
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expected if the products originally contained additional mass downstream of the TCS (i.e., 
appended to the C-terminus of 3xHA-NL-TCS). Because the truncated mRNA substrate used 
for ScIVT contained no sequences downstream of the TCS, this additional mass was 
necessarily untemplated and therefore consistent with CAT tails. Notably, the prominent 
peptidyl–tRNA species that accumulated at early time points was largely absent after 60 
minutes of translation (Figure 1-1A and 1-1B), presumably due to peptidyl–tRNA hydrolysis that 
occurred after untemplated elongation of the nascent chain. 
In addition to being C-terminal and untemplated, another known feature of CAT tails is 
that their synthesis is strictly dependent on Rqc2p but not on Ltn1p or Rqc1p (Choe et al., 2016; 
Defenouillère et al., 2016; Shen et al., 2015; Yonashiro et al., 2016). To determine if the ~23–
43-kDa mass-shifted species share this property, we took advantage of the genetic tractability of 
S. cerevisiae and non-essential nature of the RQC by performing ScIVT using extracts prepared 
from ltn1Δ, rqc1Δ, and rqc2Δ strains. While reactions using ltn1Δ and rqc1Δ extracts yielded all 
of the mass-shifted products observed when using wild-type (WT) extracts (Figure 1-1C), 
reactions using rqc2Δ extracts did not (Figure 1-1D), consistent with those species 
corresponding to CAT-tailed protein. However, rather than producing the expected 23-kDa 
3xHA-NL protein, reactions lacking Rqc2p generated a relatively stable 43-kDa peptidyl–tRNA 
species, indicating a defect in peptidyl–tRNA hydrolysis. This finding suggests that in addition to 
facilitating the incorporation of untemplated amino acids, Rqc2p may also be involved in 
promoting hydrolysis of the final peptidyl–tRNA bond and thereby liberating the nascent 
polypeptide. 
Previous biochemical and structural studies have suggested that Rqc2p engagement 
and subsequent CAT tailing must be preceded by ribosome splitting, which exposes the P-site 
tRNA and the surface of the Sarcin-Ricin loop (SRL) that are recognized by Rqc2p/NEMF 
(Lyumkis et al., 2014; Shao et al., 2015; Shen et al., 2015). In the case of truncated mRNAs that 
generate a ribosome stalled at the mRNA 3′ end with an empty A site, ribosome splitting is 
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effected by the release-factor mimics Hbs1p and Dom34p (Shao et al., 2013; Shoemaker et al., 
2010). Accordingly, ScIVT of a truncated mRNA in hbs1Δ or dom34Δ extracts generated only 
the ~43-kDa product corresponding to an especially stable peptidyl–tRNA (Figure 1-1E), which 
is presumably protected within a stalled but intact 80S ribosome. Collectively, these data 
demonstrate that ScIVT of a truncated mRNA generates polypeptides containing untemplated 
Rqc2p-dependent C-terminal extensions. Although we have not been able to confirm that these 
extensions are composed of alanine and threonine residues (for technical reasons), we suspect 
that this is the case and therefore refer to the extensions as CAT tails for simplicity. 
The lack of CAT-tailing activity in rqc2Δ extracts (Figure 1-1D) is consistent with 
previous observations that CAT tails are absent from rqc2Δ strains in vivo (Choe et al., 2016; 
Defenouillère et al., 2016; Shen et al., 2015; Yonashiro et al., 2016), which could reflect either a 
direct role for Rqc2p in CAT tailing (as suggested by structural studies) or indirect effects of 
RQC2 disruption on CAT tailing. To distinguish between these possibilities, we tested whether 
the absence of CAT-tailing activity in rqc2Δ extracts could be rescued by adding purified Rqc2p 
to ScIVT reactions already in progress. Remarkably, the addition of exogenous Rqc2p (Figure 
1-S1) to rqc2Δ extracts restored both CAT-tail synthesis and peptidyl–tRNA hydrolysis, whereas 
the addition of a CAT-tailing-deficient Rqc2p mutant containing the D98A substitution (Shen et 
al., 2015; Yonashiro et al., 2016) did not promote either CAT-tail synthesis or robust peptidyl–
tRNA hydrolysis (Figure 1-1F). These results provide direct evidence that Rqc2p is 
biochemically required for CAT tailing, consistent with its proposed role in recruiting alanine- 
and threonine-charged tRNAs to the 60S subunit (Shen et al., 2015). Also, our ability to 
temporally separate CAT tailing from canonical translation in vitro (by the addition of exogenous 
Rqc2p to rqc2Δ extracts) provided an experimental strategy for specifically testing the 
requirements of CAT-tail elongation. 
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Mechanistic differences between CAT-tail synthesis and canonical translation 
 Though previous structural studies of the RQC were instrumental in discovering CAT 
tailing and suggested a direct role for Rqc2p in the process (Shen et al., 2015), the mechanism 
of CAT tailing has only been inferred from these data and otherwise remains poorly 
characterized. In particular, no published studies have investigated the extent to which CAT 
tailing by the 60S subunit is mechanistically similar to canonical elongation by the 80S 
ribosome. To address this question, we sought to examine the sensitivity of in vitro CAT tailing 
to a collection of well-characterized chemical inhibitors that target different sites of the ribosome 
or elongation factors (Figure 1-2A) and thereby interfere with canonical translation. Importantly, 
because canonical translation is required to generate the substrate for the RQC (i.e., a stalled 
ribosome at the post-splitting stage), it was necessary to temporally separate canonical 
translation from CAT tailing to isolate the effects of these inhibitors on the latter reaction. To do 
so, we first translated a truncated mRNA in rqc2Δ extracts in the absence of any inhibitors for 
20 minutes to generate a pool of RQC substrate (60S:peptidyl–tRNA). We then supplemented 
the reactions with one of the inhibitors (at a concentration that completely inhibited canonical 
translation in vitro; Figure 1-S2A) and purified Rqc2p (Figure 1-S2B) (or a buffer-only control) to 
initiate CAT-tail synthesis. Finally, we allowed the reactions to proceed for an additional 40 
minutes before analyzing the products by immunoblotting.  
As predicted by the structural analyses, treatment with drugs that target the peptidyl-
transferase center (PTC) of the 60S subunit (anisomycin and the chain terminator puromycin) 
completely prevented CAT-tail synthesis, providing direct evidence that the catalytic activity of 
the ribosome is required for CAT tailing (Figure 1-2B and C). Puromycin treatment also resulted 
in a complete collapse of the 43-kDa mass-shifted species to 23 kDa, confirming the identity of 
this larger species as peptidyl–tRNA (Figure 1-2B). In contrast to the dramatic effects of PTC 
inhibitors, inhibitors that target the 40S subunit (emetine and G418) did not inhibit CAT-tail 
synthesis (Figure 1-2B), consistent with the proposed 40S subunit–independent mechanism of 
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CAT tailing. Surprisingly, cycloheximide—which binds in the E site of the 60S subunit and 
sterically clashes with the 3′ end of the deacylated tRNA during canonical translation—did not 
inhibit CAT tailing (Figure 1-2B). Cycloheximide insensitivity identifies an unanticipated feature 
of CAT-tail elongation that may reflect a distinct mechanism of deacylated-tRNA displacement in 
the absence of mRNA and the 40S subunit.  
It was previously proposed that specific Rqc2p–tRNA interactions impart selectivity for 
alanine- and threonine-tRNAs to CAT-tail elongation (Shen et al., 2015). However, it is not 
known if the translation elongation factors eEF1a and eEF2—which deliver aminoacyl-tRNAs to 
the ribosome and promote translocation, respectively—collaborate with Rqc2p to facilitate CAT-
tail synthesis. Strikingly, we found that drugs targeting either eEF1a or eEF2 (didemnin variants 
(Carelli et al., 2015) or sordarin (Justice et al., 1998), respectively) had no effect on CAT tailing 
(Figure 1-2C). Because many canonical translation factors are GTPases, including eEF1a and 
eEF2, we also examined whether CAT tailing requires GTP hydrolysis. We tested for inhibition 
by the non-hydrolyzable GTP analog GMP-PCP, using a similar approach as before except that 
at the time of Rqc2p addition we stopped translation by adding emetine to prevent ongoing 
translation in the GTP control reaction. Consistent with the above differences between CAT-tail 
elongation and translation, treatment with GMP-PCP had no impact on CAT tailing (Figure 1-
2D), indicating that this mRNA-independent elongation mechanism does not require energy 
from GTP hydrolysis or the canonical activities of the translational GTPases eEF1a and eEF2. 
Collectively, these findings provide direct evidence that CAT tailing is a 40S subunit–
independent, PTC-catalyzed reaction and identify key differences from canonical translation that 
suggest an entirely different elongation cycle.   
Ltn1p- and Rqc1p-dependent ubiquitination in the yeast cell-free system 
 The ability of ScIVT to recapitulate Rqc2p-dependent CAT tailing (Figure 1-1) led us to 
explore whether this system also recapitulates the other key activity of the RQC, Ltn1p-
dependent nascent-chain ubiquitination. Initial experiments comparing a lysine-containing 
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truncated reporter mRNA to a lysine-free version revealed a faint smear of high-molecular-
weight (HMW) products (~50–115 kDa) unique to the lysine-containing reporter (Figure 1-3A, 
compare lanes 1 and 4). We reasoned that these HMW products were likely ubiquitinated 
proteins because lysine residues are the canonical ubiquitination sites (Pickart, 2001). However, 
because ScIVT extracts contain many ubiquitin ligase activities and a finite pool of endogenous 
ubiquitin, we suspected that Ltn1p-dependent ubiquitination of the reporter protein (which 
occurs late in the reactions) might have been limited by the amount of ubiquitin available to 
Ltn1p. Indeed, supplementing ScIVT reactions with exogenous ubiquitin resulted in enhanced 
accumulation of the lysine-dependent HMW products (Figure 1-3A). Treatment of ubiquitin-
supplemented reactions with TEV protease or RNase did not fully collapse the HMW species as 
it did for CAT-tailed species (Figure 1-3B), consistent with the HMW species containing 
ubiquitin-modified residues rather than simply having exceptionally long CAT tails. To directly 
demonstrate that these HMW species contained ubiquitin, we translated truncated mRNAs (with 
or without lysines) in the presence of exogenous Myc-tagged ubiquitin and purified the reporter 
protein under denaturing conditions, followed by immunoblotting to detect Myc-tagged ubiquitin. 
In reactions conducted with WT extracts, we readily detected Myc-tagged ubiquitin within the 
purified HMW species (Figure 1-3C, fourth lanes in left and right panels). 
As expected, we did not observe ubiquitination of the reporter protein in reactions 
performed with ltn1Δ extracts (Figure 1-3C and Figure 1-4A), consistent with Ltn1p being the 
responsible E3 ubiquitin ligase. The addition of purified Ltn1p to ltn1Δ extracts restored 
ubiquitination, while the addition of purified Ltn1p containing the W1542E substitution—a RING 
domain mutant that does not support protein turnover in vivo (Bengtson and Joazeiro, 2010)—
did not (Figure 1-4A and Figure 1-S3). These results demonstrate that the lack of ubiquitination 
in ltn1Δ extracts is a direct consequence of the absence of Ltn1p rather than an indirect effect. 
Collectively, these results demonstrate that in addition to Rqc2p-dependent CAT tailing the 
ScIVT system we established also recapitulates Ltn1p-dependent ubiquitination, as previously 
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shown for lysates derived from N. crassa and rabbit reticulocytes (Doamekpor et al., 2016; Shao 
et al., 2013).  
 Unexpectedly, we did not detect any Ltn1p-dependent ubiquitination of the reporter 
protein in rqc1Δ extracts (Figure 1-3C). The addition of purified Rqc1p (Figure 1-S3), however, 
fully rescued ubiquitination in rqc1Δ extracts (Figure 1-3C and Figure 1-4B). Increasing the 
concentration of Ltn1p in the reaction did not bypass the requirement for Rqc1p in ubiquitination 
(Figure 1-S4). These observations suggest that Rqc1p is directly involved in nascent-chain 
ubiquitination. Such a role is consistent with the fact that LTN1 deletion phenocopies RQC1 
deletion in both the accumulation of stalling reporters in vivo and, more broadly, in their 
correlated set of genetic interactions (Brandman et al., 2012; Defenouillère et al., 2013). 
Although TCF25/Rqc1p was previously reported to be dispensable for Listerin/Ltn1p-mediated 
ubiquitination of purified 60S-bound stalled nascent chains (Shao and Hegde, 2014), the 
stringent purification of ribosome–nascent chain complexes in that study might have removed 
factors that otherwise impose a requirement for Rqc1p/TCF25 (e.g., chaperones that protect the 
nascent chain). Our results support a model in which Rqc1p directly promotes Ltn1p-mediated 
ubiquitination of the nascent chain via a mechanism that remains to be determined.  
Interplay between CAT tailing and ubiquitination 
Previous studies have shown that a CAT-tailing-deficient mutant of Rqc2p preserves 
degradation of stalled nascent chains (Shen et al., 2015) and that in vitro reconstitution of 
Listerin/Ltn1p-mediated ubiquitination does not strictly require NEMF/Rqc2p (Shao and Hegde, 
2014; Shao et al., 2013). Together, these studies suggested that CAT tailing is dispensable for 
degradation of the assayed reporter constructs. Based on these results and structural data, it 
was proposed that Rqc2p indirectly contributes to ubiquitination by recognizing the aberrant 
60S:peptidyl–tRNA complex, stabilizing Ltn1p on the 60S subunit, and sterically preventing the 
40S subunit from rejoining (Shao et al., 2015). Together with the minimal impact of LTN1 
disruption on CAT tailing in vivo (Choe et al., 2016; Defenouillère et al., 2016; Shen et al., 2015; 
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Yonashiro et al., 2016) and in vitro (Figure 1-1), these studies led to a model in which 
ubiquitination by Ltn1p and CAT tailing by Rqc2p are independent activities of the RQC (Inada, 
2017). 
 The unique ability of our ScIVT system to recapitulate both activities of the RQC, 
combined with its genetic tractability, allowed us to directly test this model in vitro. Consistent 
with the proposed scaffolding function of Rqc2p in ubiquitination, disruption of RQC2 abrogated 
nascent-chain ubiquitination by Ltn1p (Figure 1-3C and Figure 1-4C), and addition of wild-type 
Rqc2p rescued ubiquitination (Figure 1-4C and Figure 1-S1). Unexpectedly, however, the 
addition of CAT-tailing-deficient (D98A) Rqc2p to rqc2Δ extracts only partially rescued 
ubiquitination (Figure 1-4C). Similarly, reactions using extracts containing endogenously 
expressed Rqc2p(D98A) as the only RQC2 gene product yielded minimal ubiquitinated protein 
(Figure 1-3C). To rule out the possibility that the effect of the D98A substitution on ubiquitination 
was due to disruption of the known scaffolding function of Rqc2p, we took an alternative 
approach to inhibit CAT tailing in the context of wild-type Rqc2p. As observed in the 
Rqc2p(D98A) experiments, preventing CAT tailing of stalled nascent chains—in this case with 
anisomycin treatment (Figure 1-2C)—substantially reduced ubiquitination (Figure 1-4D and 
Figure 1-S5). These results suggest that Rqc2p not only provides structural support for Ltn1p 
but also that CAT tailing directly enhances Ltn1p-dependent ubiquitination of at least some 
substrates (see Discussion). Collectively, our in vitro analyses reveal that all three components 
of the RQC—Ltn1p/Listerin, Rqc1p/TCF25, and Rqc2p/NEMF—contribute to ubiquitination of 
the nascent chain. 
 Structural studies of full-length Listerin on the 60S subunit localized its active-site-
containing RING domain near the ribosomal exit tunnel (Shao et al., 2015), poised to facilitate 
ubiquitination of lysine residues recently emerged from the tunnel. At the same time, the implied 
physical tethering of the RING domain to the ribosome suggests that the active site may not be 
able to access more distantly positioned lysines in the nascent polypeptide, nor can the most 
	 16 
recently translated lysines—contained within the 30–60-amino-acid long exit tunnel (Kramer et 
al., 2009)—be accessed by Ltn1p until their emergence. Collectively, these physical constraints 
suggest that only a limited subset of lysines in stalled nascent chains are accessible to the 
active site of Ltn1p, with other lysines either being either too far from the RING domain or buried 
in the ribosomal exit tunnel. We reasoned that CAT tailing could therefore expose the latter 
class of “hidden” lysine residues to the RING domain of Ltn1p. 
 To evaluate this model of CAT-tailing-dependent ubiquitination, we used the 
aforementioned denaturing purification assay (Figure 1-3) to compare the extent of nascent-
chain ubiquitination in the absence versus the presence of CAT tailing (i.e., ScIVT extracts 
containing Rqc2p(D98A) versus Rqc2p) across a set of truncated mRNAs encoding lysine 
residues at different positions (Figure 1-5A) . In the absence of CAT tailing, only two of the 
lysine-containing nascent chains were efficiently ubiquitinated by Ltn1p (Figure 1-5B, top left 
panel), consistent with the limited reach of the Ltn1p RING domain in the context of a fixed 
nascent chain. In both substrates, multiple lysines were located ~30–50 residues from the 
stalling site—a distance predicted to naturally position the lysines proximal to the exit tunnel 
near the Ltn1p active site. Remarkably, however, all of the lysine-containing nascent chains 
could be detectably ubiquitinated above background in the presence of CAT tailing (Figure 1-
5B, top left panel), demonstrating that CAT tailing can greatly expand the range of suitable 
Ltn1p substrates. Most notably, nascent chains containing one (Figure 1-5A, reporter E) or three 
lysine residues (Figure 1-S6A, reporters L and M) that upon stalling should be hidden in the exit 
tunnel (i.e., 0-30 amino acids from the C terminus) were ubiquitinated in a CAT-tailing-
dependent manner, albeit weakly (but consistently above background levels seen in a lysine-
free reporter) (Figure 1-5B, top left panel, compare reporter B to E; Figure 1-S6B, compare 
reporter I to L and M). These data demonstrate that the range of Ltn1p-accessible lysine 
residues is limited by spatial constraints, and that these constraints are relaxed by CAT-tailing-
dependent exposure of lysines. 
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 We then asked if the enhancement of ubiquitination by CAT tailing observed in vitro has 
functional consequences on protein turnover in vivo. The few nascent chain RQC substrates 
previously studied in vivo were shown to be degraded in a CAT-tailing-independent manner 
(Shen et al., 2015), which we reasoned might have been due to native lysines being fortuitously 
positioned proximal to the Ltn1p RING domain. To explore the relationship between lysine 
positioning and Ltn1p-dependent protein degradation in vivo, we generated ribosome-stalling 
reporters encoding the analogous RQC substrates from our in vitro studies (see Materials and 
Methods) and assessed their steady-state levels in living budding-yeast cells. Consistent with 
our in vitro analyses (Figure 1-5B and 1-S6B) and previous studies using a native (i.e., lysine-
containing) GFP reporter (Shen et al., 2015), substrates predicted to contain exposed lysines 
near the exit tunnel did not accumulate in either WT or CAT-tailing-deficient cells (Figure 1-S6C, 
top left panel, reporters H′ and K′), indicative of efficient ubiquitination and proteasomal 
degradation. By contrast, substrates in which there were no lysines near or within the exit tunnel 
showed no evidence of RQC-dependent degradation, providing in vivo evidence for the limited 
reach of Ltn1p (Figure 1-S6C, top left panel, lanes I′ and J′). Finally, substrates that contained 
lysines within the exit tunnel were more abundant in Rqc2(D98A) cells than in WT cells, 
suggesting that for these substrates CAT tails exposed hidden lysines to Ltn1p for ubiquitination 
and subsequent degradation (Figure 1-S6C, top left panel, lanes L′ and M′). These results 
reveal that CAT tailing is required for nascent-chain ubiquitination when lysines are not 
conveniently located proximal to the Ltn1p RING domain. Additionally, in cells lacking intact 
LTN1 or RQC1, all reporters accumulated at similar steady state levels regardless of lysine 
position, demonstrating that Ltn1p and Rqc1p are required for degradation of truncated 
NanoLuc nascent chains in vivo (Figure 1-S6C, top right and bottom left panels). Broadly, these 
findings establish that for many substrates CAT tailing and ubiquitination are coupled, rather 
than distinct, activities of the RQC and provide new insight into the physiological role of CAT 
tailing. 
	 18 
 Because ribosomes could potentially stall anywhere on an mRNA during translation 
elongation, the RQC machinery would ideally be able to act on a wide range of possible nascent 
chains to facilitate degradation. However, the fact that the Ltn1p RING domain can only access 
a small window of amino acids outside the exit tunnel limits the set of suitable nascent chains 
that can be readily ubiquitinated. The ability of CAT tailing to expose lysine residues buried in 
the exit tunnel to Ltn1p would relieve this limitation, so long as the nascent chain contains a 
lysine hidden in the exit tunnel at the time of ribosome stalling. To evaluate the possible extent 
this phenomenon in S. cerevisiae, we performed a computational analysis to determine the 
fraction of all potential nascent polypeptides across the yeast proteome that encode a lysine 
predicted to be in the ribosome exit tunnel. Remarkably, we found that ~90% of all possible 
nascent polypeptides generated by a stalled ribosome would contain at least one lysine buried 
in the exit tunnel (85–96% for 30–60 amino acids of buried nascent chain as a function of 
potential secondary structure; Figure 1-5C). Moreover, non-stop mRNAs that lack a termination 
codon and are translated into the poly(A) tail (Bengtson and Joazeiro, 2010; Defenouillère et al., 
2013; Ito-Harashima et al., 2007) would also generate nascent polypeptides with lysines 
(encoded by ‘AAA’ codons) hidden in the exit tunnel, which might be an important class of CAT-
tailing-dependent ubiquitination substrates. Altogether, these results suggest that CAT tailing 
can facilitate ubiquitination of the vast majority of potential RQC substrates. For the remaining 
<15% of nascent polypeptides stalled on ribosomes without a lysine positioned near or within 
the exit tunnel, the CAT tail may facilitate protein aggregation as previously described (Choe et 
al., 2016; Yonashiro et al., 2016). However, rather than being the primary role of CAT tails, 
aggregation is more likely a backup pathway to mitigate the toxic effects of stalled polypeptides 
that cannot be immediately degraded. 
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DISCUSSION 
 We have shown that establishing a cell-free system that recapitulates both CAT tailing 
and ubiquitination opens new opportunities to explore how the fully functional RQC promotes 
clearance of aberrant translation products. Our analyses reveal that Rqc2p-mediated nascent-
chain elongation is mechanistically distinct from canonical translation, that ubiquitination of the 
nascent polypeptide requires both Ltn1p and Rqc1p, and that the ubiquitination and CAT-tailing 
activities of the RQC are coupled through a mutual requirement for active Rqc2p (Figure 1-6).   
The key benefit of an in vitro system to study CAT tailing is the ability to perform 
experiments that would be intractable in vivo. Indeed, a major difficulty in studying CAT tailing is 
that it utilizes some of the same machinery as canonical translation (i.e., the 60S subunit) and 
requires a substrate that is generated by canonical translation, making it difficult to perturb CAT 
tailing specifically. By temporally separating the translation- and CAT-tailing-phases of in vitro 
reactions, we overcame this obstacle and specifically tested the sensitivity of the CAT-tailing 
reaction to a wide range of well-characterized ribosome and translation inhibitors. These 
analyses revealed that aside from requiring the catalytic PTC of the ribosome, CAT tailing is 
otherwise fundamentally different from translation elongation in ways that could not have been 
fully anticipated from previous studies (Figure 1-2). In particular, our findings that CAT tailing 
does not require the canonical activities of the elongation factors or energy from GTP hydrolysis 
suggest a unique mechanism of elongation. Reexamining 60S:RQC structures (Shao et al., 
2015; Shen et al., 2015), we noted that the network of interactions between Ltn1p/Rqc2p and 
the 60S subunit overlaps with the ribosome-binding sites of eEF1a (Shao et al., 2016) and eEF2 
(Taylor et al., 2007). The overlap in binding sites indicates that either eEF1a/eEF2 are 
dispensable for CAT tailing, or that eEF1a/eEF2 and the RQC interact transiently with the 60S 
subunit during elongation. Our findings favor the former model and suggest that Rqc2p directly 
recruits charged tRNAs with its selective tRNA-binding activity (Shen et al., 2015), without the 
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involvement of eEF1a. Following peptide-bond formation by the 60S subunit, the A/P and P/E 
tRNAs may spontaneously translocate in the absence of interactions with an mRNA template or 
40S subunit; whereas during canonical translation such interactions impose an energy 
requirement for translocation that is fulfilled by the GTPase activity of eEF2. Given that CAT 
tailing was proposed to occur on the 60S subunit (Shen et al., 2015), we predicted that all 
translation inhibitors that bind the 60S subunit would inhibit CAT-tail synthesis. However, we 
found that CAT tailing was not inhibited by cycloheximide, suggesting that the deacylated tRNA 
may rapidly dissociate from the 60S subunit following peptidyl transfer. 
Together, these findings suggest that a minimal set of factors—a 60S:peptidyl–tRNA 
complex, charged alanine and threonine tRNAs, and Rqc2p—may be sufficient for CAT-tail 
synthesis. In 1969, Monro demonstrated that in the presence of certain alcohols, isolated 
bacterial 50S ribosomal subunits could catalyze polymerization from aminoacyl-tRNAs in the 
absence of an mRNA template and 30S subunits (Monro, 1969). Thus, it is conceivable that 
Rqc2p may stimulate nascent-chain elongation much as in Monro’s minimal prokaryotic system. 
Many questions remain about Rqc2p dynamics during CAT tailing, including whether a single 
molecule of Rqc2p remains on the 60S subunit for successive cycles of peptide-bond formation 
or whether each cycle of elongation requires binding by a new Rqc2p–tRNA complex.  
CAT-tail synthesis eventually terminates by hydrolysis of the peptidyl–tRNA linkage, 
which is presumably needed to release the CAT-tailed nascent chain from the 60S subunit for 
its destruction by the proteasome. Indeed, one critical function of CAT tailing might be to provide 
a mechanism of termination in the absence of a stop codon. The wide range of CAT-tail lengths 
observed both in vivo (Choe et al., 2016; Defenouillère et al., 2016; Shen et al., 2015; Yonashiro 
et al., 2016) and in vitro suggests that termination is a stochastic process. Furthermore, our 
finding that peptidyl–tRNA intermediates are relatively stable in vitro in the absence of Rqc2p 
(Figures 1-1D and 1-1F, Figure 1-2, and Figure 1-4C) indicates a potentially direct role of Rqc2p 
in the termination reaction. These observations lead to a model for CAT-tailing termination in 
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which Rqc2p recruits a termination factor to the 60S subunit in a stochastic manner during the 
process of elongation. Because Rqc2p interacts with A-site tRNAs at a site distant from the 
acceptor stem (Shen et al., 2015), it is possible that the “termination factor” is an uncharged 
alanine- or threonine-tRNA (Caskey et al., 1971; Zavialov et al., 2002). Alternatively, Rqc2p 
might interact with the canonical termination factor eRF1 or another protein with peptidyl–tRNA 
hydrolase activity to facilitate termination.  
Taking advantage of the fact that our extracts also recapitulated Ltn1p-dependent 
ubiquitination, we found that Rqc1p plays a critical role in nascent-chain ubiquitination in vitro 
(Figure 1-3C and Figure 1-4B). This direct role of Rqc1p in ubiquitination contrasts with its 
previously suggested role in recruiting Cdc48p downstream of ubiquitination (Brandman et al., 
2012; Defenouillère et al., 2013). Nevertheless, our discovery that ubiquitination in vitro is as 
dependent on Rqc1p as it is on the E3 ligase Ltn1p is consistent with the fact that yeast strains 
lacking Rqc1p and Ltn1p have very similar phenotypes and genetic interaction profiles, 
suggesting a similar molecular defect in these strains (Brandman et al., 2012). We speculate 
that Rqc1p may facilitate ubiquitination by positioning the nascent chain in proximity to the Ltn1p 
RING domain, by promoting binding of the E2 ubiquitin-conjugating enzyme, or by activating 
Ltn1p’s E3 ligase activity on the 60S subunit.   
 With a system that uniquely recapitulates both nascent-chain elongation by Rqc2p and 
ubiquitination by Ltn1p, we discovered that Rqc2p can elongate the nascent chain to enhance 
ubiquitination, rather than just providing structural support for Ltn1p binding to the 60S subunit 
(Figure 1-3C and Figure 1-4C). This finding was surprising given that previous studies have 
shown that a CAT-tailing-deficient mutant of Rqc2p preserves degradation of aberrant nascent 
chains in yeast cells (Shen et al., 2015) and that in vitro reconstitution of Listerin/Ltn1p-
mediated ubiquitination does not strictly require NEMF/Rqc2p (Shao and Hegde, 2014). How 
can we reconcile these findings? Structural studies of full-length Listerin/Ltn1p on the 60S 
subunit localized its RING domain (which binds an E2 ubiquitin-conjugating enzyme) near the 
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ribosomal exit tunnel (Shao et al., 2015), poised to facilitate ubiquitination of lysine residues 
close to or recently emerged from the tunnel. The physical tethering of the RING domain near 
the exit tunnel suggests that Ltn1p may not be able to access more distantly positioned lysines 
in the nascent polypeptide, nor can the most recently translated lysines—contained within the 
30–60-amino-acid long exit tunnel (Kramer et al., 2009)—be accessed by Ltn1p until their 
emergence. Our observations lead to a model in which Ltn1p can only ubiquitinate a spatially 
restricted set of lysines, while CAT tailing enables access to other lysines—as previously 
proposed (Brandman and Hegde, 2016; Simms et al., 2017). We reason that the few nascent 
chain RQC substrates previously studied in vivo could be degraded in a CAT-tailing-
independent manner (Choe et al., 2016; Defenouillère et al., 2016; Shen et al., 2015; Yonashiro 
et al., 2016) due to native lysines being fortuitously positioned proximal to the Ltn1p RING 
domain. 
Recent studies in budding yeast have demonstrated that CAT tails mediate formation of 
detergent-insoluble aggregates when the nascent chain cannot be degraded due to its limited 
ubiquitination potential or due to inactivation of Ltn1p (Choe et al., 2016; Defenouillère et al., 
2016; Yonashiro et al., 2016). In the context of a fully intact RQC, however, our findings suggest 
that CAT tailing and ubiquitination are interdependent activities. Elongation of the nascent chain 
with CAT tails can result in two outcomes: positioning lysine residues proximal to the Ltn1p 
RING domain for efficient ubiquitination; or distancing lysine residues from the Ltn1p RING 
domain, making ubiquitination less efficient. Thus, CAT tailing and ubiquitination must be tightly 
coordinated to promote nascent-chain degradation and to avoid, where possible, aggregate 
formation and the detrimental sequestration of cytosolic chaperones. These studies collectively 
suggest that rather than being the primary role of CAT tails, aggregation is more likely a backup 
pathway to mitigate the toxic effects of stalled polypeptides that cannot be efficiently 
ubiquitinated and degraded (Figure 1-6). A notable distinction between the aggregation- and 
ubiquitination-promoting functions of CAT tails is that the former depends on the 
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alanine/threonine composition of the CAT tail (Choe et al., 2016), while the latter depends on 
the process of CAT tailing itself.   
While CAT tailing has yet to be reported in metazoans, the conservation of 
Rqc1p/TCF25, Rqc2p/NEMF, and Ltn1p/Listerin—including critical residues that we mutated in 
this study—suggest that both RQC activities are conserved and together provide a means of 
protecting cells against the accumulation of faulty translation products. Ltn1p-dependent 
ubiquitination has been detected in rabbit reticulocyte extracts, so a CAT-tailing-dependent 
mechanism to facilitate ubiquitination of inaccessible lysine residues likely operates in 
metazoans as well. Underscoring the importance of this quality-control mechanism in 
maintaining proteostasis, mutations in the mammalian homologs of HBS1 (Ishimura et al., 2014) 
and LTN1 (Chu et al., 2009) cause neurodegeneration in mice.  
With our newfound insights, the similarities between the bacterial tmRNA system and the 
eukaryotic RQC become even more striking than previously appreciated. In certain bacteria, a 
stalled ribosome is rescued by the recruitment of a hybrid tRNA/mRNA-like molecule (tmRNA) 
to the empty A-site of the ribosome, leading to translation of a tmRNA-encoded C-terminal 
degron that includes a dedicated stop codon (Moore and Sauer, 2007). In this way, stalled 
nascent chains are marked for degradation and translation can terminate even when the mRNA 
template lacks a stop codon. The RQC fulfills these same functions but in a different manner 
that is compatible with the ubiquitin-proteasome system: Stalled nascent chains are marked for 
degradation by ubiquitination (in certain cases facilitated by CAT tailing), and translation can 
terminate without a stop codon with the help of Rqc2p. Thus, both mechanisms involve a 
ribosome-catalyzed peptidyl-transferase reaction that adds a C-terminal extension that is not 
templated by the parent mRNA molecule. The addition of the C-terminal extension, moreover, 
facilitates peptidyl–tRNA hydrolysis and nascent-chain release either directly (tmRNA) or 
indirectly (RQC) to promote degradation. These functional similarities between the tmRNA 
system and the RQC—despite not sharing any related factors other than the ribosome—provide 
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a striking example of convergent evolution that emphasizes the physiological importance of 
discarding incompletely synthesized proteins and recycling the translation machinery. 
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MATERIALS AND METHODS  
Yeast Strain Construction  
 Saccharomyces cerevisiae strains used in this study were derived from BY4741 (MATa 
his3Δ1  leu2Δ0 met15Δ0 ura3Δ0) and are listed in Supplementary file 1. Yeast transformations 
were performed using the PEG–lithium acetate method (Gietz and Woods, 2006). To generate 
gene knockouts, the entire coding sequence of the gene of interest was replaced with the URA3 
cassette of pRS416. Strains containing point mutations at endogenous loci were generated from 
URA3-disrupted strains by transformation with PCR fragments encoding the mutant gene of 
interest and 5-FOA counterselection (Boeke et al., 1987). Transformants were screened by 
PCR to identify integrants, which were subsequently verified by PCR and Sanger sequencing of 
the entire integrated cassette.   
 
Preparation of mRNA for In Vitro Translation  
 pcDNA3.1(+) (Thermo Fisher Scientific, Waltham, MA) was modified using Gibson 
Assembly Master Mix (New England Biolabs, Ipswich, MA) and appropriate DNA fragments 
according to the Gibson assembly method (Gibson et al., 2009) to generate pBAO1124, which 
contains (in order): T7 promoter, 46-nt 5′-UTR lacking any AUG or near-AUG codons (i.e., NUG, 
ANG, or AUN, where N is any nucleotide), 3xHA-NanoLuc luciferase ORF, 56-nt 3′-UTR, and 
50-nt poly(A) sequence. RNAs were generated by run-off transcription with T7 RNA Polymerase 
using the MEGAscript T7 Transcription Kit (Thermo Fisher Scientific) according to the 
manufacturer’s instructions using PCR-amplified DNA templates derived from pBAO1124 or its 
variants. Transcription reactions were terminated by addition of ammonium acetate stop 
solution. RNA was extracted with neutral phenol:chloroform:isoamyl alcohol (25:24:1) (Sigma, 
St. Louis, MO), precipitated with ethanol, and resuspended in nuclease-free water. A 5′-7-
methylguanosine cap was added to RNA post-transcriptionally using the Vaccinia Capping 
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System (New England Biolabs). Capping reactions were desalted using Micro Bio-Spin 
Columns with Bio-Gel P-30 (Bio-Rad, Hercules, CA) before RNA was extracted with phenol, 
precipitated with ethanol, and resuspended in nuclease-free water.  
 
S. cerevisiae In Vitro Translation Extract Preparation  
 S. cerevisiae strains were grown overnight to saturation in rich YPAD media, diluted the 
next morning to OD600 0.2 in a total volume of 1 L YPAD, and harvested at OD600 1.4–1.8 by 
centrifugation at 3500 rpm for 6 min at 4°C. The cell pellet was washed with water and 
resuspended in lysis buffer A (30 mM HEPES-KOH pH 7.4, 100 mM KOAc, 2 mM Mg(OAc)2, 
2mM DTT, and cOmplete mini EDTA-free protease inhibitor cocktail [Roche, Switzerland]) using 
1 ml per 6 g of wet cell pellet. The cell slurry was dripped into liquid nitrogen to produce frozen 
pellets, which were then pulverized using a 6970EFM Freezer/Mill (SPEX SamplePrep, 
Metuchen, NJ) by three cycles of 12 Hz agitation for 1.5 min with cooling for 2 min after each 
cycle. The resulting “grindate” was combined with an equal volume of pre-chilled lysis buffer A 
(i.e., 1 ml per 1 g of grindate) and allowed to thaw on ice. Cell debris was cleared by sequential 
centrifugation at 4°C at 1000g for 5 min, 1350g for 5 min, 14000g for 30 min, and finally 14000g 
for an additional 10 min. The clarified lysate was dialyzed twice for 2 hr against 250 ml lysis 
buffer A (except without protease inhibitor cocktail) using 3500 MWCO cassettes (Thermo 
Fisher Scientific #87722). After dialysis, lysates were flash frozen in 50 µl aliquots in liquid 
nitrogen and stored at –80°C.  
 
S. cerevisiae In Vitro Translation  
 Endogenous mRNAs in thawed extracts were degraded by treatment with 0.3 U/µl 
micrococcal nuclease (MNase) and 480 µM CaCl2 for 10 min at room temperature, followed by 
addition of 2 mM EGTA and transfer to ice. ScIVT reactions were initiated by adding m7G-
capped RNA (40 ng per µl of reaction volume) to MNase-treated yeast extracts and incubating 
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at 25°C for up to 90 min. Final concentrations of reaction components were 48.67% (v/v) 
MNase-treated yeast extract, 22 mM HEPES-KOH (pH 7.4), 120 mM potassium acetate, 1.5 
mM magnesium acetate, 0.75 mM ATP, 0.1 mM GTP, 0.04 mM each amino acid, 1.7 mM DTT, 
25 mM creatine phosphate, 0.34 µg/µl creatine kinase, 0.14 U/µl SUPERase In RNase Inhibitor 
(Thermo Fisher Scientific), and 0.16X cOmplete mini EDTA-free protease inhibitor cocktail 
(Roche). Where indicated, reactions also included 10 or 100 µM recombinant human ubiquitin or 
Myc-ubiquitin (Boston Biochem, Cambridge, MA). Reactions were halted by transferring to ice 
or by adding an equal volume of 2X Laemmli Sample Buffer (Bio-Rad). The results shown for all 
ScIVT experiments are representative of at least two technical replicates (i.e., experiments 
conducted with independently prepared reagents).  
 
Denaturing Purification of ScIVT Products 
 30 µl ScIVT reactions were assembled with 1.2 µg 10xHis-3xHA-NL mRNAs and 10 µM 
recombinant Myc-ubiquitin (Boston Biochem) and incubated at 25°C for 1 hr. For input samples, 
10 µl was removed and quenched in an equal volume of 2X Laemmli Sample Buffer. For Ni-
NTA-purified samples, the remaining 20 µl was quenched by addition of denaturing buffer (6 M 
guanidine-HCl, 50 mM Tris pH 7.8, 300 mM KCl, 10 mM imidazole, 0.1% NP-40, 5 mM β-
mercaptoethanol [βME]), and then incubated with 10 µl of pre-washed Ni-NTA Magnetic 
Agarose Beads (Qiagen, Germany) at 4°C overnight with end-over-end rotation. Beads were 
washed three times with wash buffer I (denaturing buffer except 500 mM KCl) and three times 
with wash buffer II (denaturing buffer except 50 mM KCl and no guanidine-HCl), each for 5 min 
at room temperature. Bound proteins were eluted from beads by adding 15 µl elution buffer 
(wash buffer II except 200 mM imidazole) and incubating at 22°C for 5 min with shaking at 1000 
rpm. The elution step was repeated, and eluates were pooled and mixed with an equal volume 
of 2X Laemmli Sample Buffer. The results shown for all experiments that include a denaturing 
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purification of ScIVT products are representative of at least three technical replicates (i.e., 
experiments conducted with independently prepared reagents). 
 
Immunoblotting 
 Protein samples were separated by SDS-PAGE using 12% Bolt Bis-Tris gels (Thermo 
Fisher Scientific) and transferred in 1X CAPS Buffer onto 0.22 micron PVDF membrane (Bio-
Rad). Blots were probed with the following antibodies diluted 1:5000 in 1X TBS-T containing 5% 
nonfat dry milk: mouse anti-HA (RRID:AB_627809, Santa Cruz Biotechnology [Dallas, TX] sc-
7392), rat anti-HA high sensitivity (RRID:AB_390918, Roche #11867423001), mouse anti-Myc 
(RRID:AB_331783, Cell Signaling Technology [Danvers, MA] #2276), HRP-conjugated goat 
anti-mouse IgG (RRID:AB_631736, Santa Cruz Biotechnology sc-2005), and HRP-conjugated 
goat anti-rat IgG (RRID:AB_631755, Santa Cruz Biotechnology sc-2032). Blots were developed 
using Clarity ECL Western Blotting Substrate (Bio-Rad), and chemiluminescence was detected 
on a ChemiDoc Imaging System (Bio-Rad). 
 
Protein Purification  
 S. cerevisiae strain yRH101 (a gift from Stephen Bell, MIT) derived from ySC7 (Chen et 
al., 2007) containing a 2 µm PGAL1-[protein]-10xHis plasmid (a gift from Bob Stroud, UCSF) was 
grown overnight in SC–His media containing 2% raffinose, diluted the next day, and grown for 
an additional night to early saturation. Protein expression was induced by adding an equal 
volume of Yeast-Peptone media containing 2% galactose, and cells were grown for 5 hr at 
30°C. Cells were harvested by centrifugation at 3500 rpm for 6 min at 4°C, and the cell pellet 
was washed with water before resuspending in Lysis Buffer (20 mM HEPES-KOH pH 7.4, 500 
mM KCl, 20 mM imidazole; 2 mM βME and cOmplete EDTA-free protease inhibitor cocktail 
[Roche] added just prior to use) at a ratio of 1 ml per gram of cell pellet. The resulting cell slurry 
was dripped into liquid nitrogen to produce frozen pellets, which were pulverized using a 
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6970EFM Freezer/Mill (SPEX SamplePrep) by three cycles of 12 Hz agitation for 1.67 min with 
2 min cooling after each cycle. The resulting powder was briefly thawed before adding Lysis 
Buffer (1 mL per 1 g of powder) supplemented with additional protease inhibitors (292 µM 
Pepstatin, 8.4 mM Leupeptin, 1.23 mM Aprotinin, 1 mM Phenylmethylsulfonyl fluoride [PMSF]). 
Cell debris was cleared by sequential centrifugation at 4000 rpm at 4°C for 10 min and then 30 
min, followed by sequential filtration through 2.7 and 1.6 µm Whatman GD/X filters (GE 
Healthcare Life Sciences, Marlborough, MA). His-tagged proteins were purified from lysate 
using Ni-NTA Sepharose beads (Qiagen) as follows. Beads (~1 ml 50% slurry per 1 L yeast 
culture) were washed with water and equilibrated in Lysis Buffer. Lysate was added to semi-dry 
beads and rotated at 4°C for 2 hr. Beads were collected by centrifugation at 800 rpm for 3 min, 
resuspended in an equal volume of Lysis Buffer, loaded over a disposable Bio-Spin column 
(Bio-Rad), and washed once with 10 ml Lysis Buffer. The column was then washed as follows: 
once with 10 ml Wash Buffer (20 mM HEPES-KOH pH 7.4, 500 mM KCl, 10% glycerol, 2 mM 
βME) containing 20 mM imidazole and 1 mM PMSF; once with 10 ml Wash Buffer containing 20 
mM imidazole; and twice with 10 ml Wash Buffer containing 50 mM imidazole. Proteins were 
sequentially eluted from the beads by gravity rinses as follows: once with 250 µl Wash Buffer 
containing 250 mM imidazole; twice with 500 µl Wash Buffer containing 250 mM imidazole; and 
twice with 500 µl Wash Buffer containing 500 mM imidazole. Elution fractions were analyzed by 
SDS-PAGE and staining with Coomassie Brilliant Blue R-250 to identify those containing the 
protein of interest, which were then pooled and concentrated to ~500 µl before overnight 
dialysis into Rqc2p/Ltn1p Storage Buffer (50 mM HEPES-KOH pH 7.4, 300 mM KOAc, 5% 
glycerol, 2 mM DTT) or Rqc1p Storage Buffer (20 mM HEPES-KOH pH 7.4, 500 mM KOAc, 
10% glycerol, 2 mM DTT). Dialyzed protein was passed through a 0.1 µm centrifugal filter (EMD 
Millipore [Hayward, CA] #UFC30VV00) before flash freezing in liquid nitrogen. Protein 
concentration was determined by both spectrophotometry using a Nanodrop 2000 (Thermo 
Fisher Scientific) and Coomassie staining against BSA standards. 
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Figure 1-1. An S. cerevisiae in vitro translation system recapitulates synthesis of Rqc2p-
dependent polypeptide extensions. 
 (A) Time courses of S. cerevisiae in vitro translation (ScIVT) reactions. ScIVT reactions were 
prepared using wild-type (WT) extracts and 1 µg of either a full-length (left; includes a stop codon and 3′-
UTR) or truncated (right; encodes a terminal valine residue) mRNA encoding lysine-free 3xHA-NanoLuc 
(3xHA-NL). At the indicated time points, aliquots of the reactions were quenched in 2X Laemmli Sample 
Buffer. Proteins were separated by SDS-PAGE, and HA-tagged translation products were visualized by 
immunoblotting. ‘Long’ and ‘Short’ refer to exposure times of the blots. (B) Analyses of mass-shifted 
products. An ScIVT reaction was prepared using WT extracts and a lysine-free truncated mRNA 
substrate that also encodes a TEV cleavage site (TCS). Translation was halted after 15 or 60 minutes by 
addition of 20 mM EDTA, after which reactions were treated without (–) or with (+) TEV and/or RNase 
A/T1 cocktail for 60 minutes. Translation products were analyzed by immunoblotting as in (A). (C–E) 
Genetic analysis of mass-shifted products. ScIVT reactions were prepared using extracts from strains of 
the indicated genotypes and a lysine-free truncated mRNA substrate. Reactions were performed and 
analyzed as in (A) but with less mRNA (480 ng). The species that migrate just below the peptidyl–tRNA in 
rqc2Δ extracts in (D) represent peptidyl–tRNA degradation products that arise due to prolonged 
incubation in the absence of Rqc2p. (F) Rescuing Rqc2p deficiency in vitro. ScIVT reactions were 
prepared using rqc2Δ extracts and a lysine-free truncated mRNA substrate. After 30 min of translation, 
reactions were supplemented with either protein storage buffer (–) or purified Rqc2p (WT or CAT-tailing 
deficient D98A at 420 nM final concentration) and indicated time points were analyzed by SDS-PAGE and 
immunoblotting. Dashed lines indicate where intervening lanes were removed for clarity. 
  
	 39 
 	
Figure 1-2. CAT-tail synthesis is mechanistically distinct from canonical translation. 
 (A) Schematics of small-molecule inhibitors that directly bind the ribosome (top) or that target the 
translation elongation factors eEF1a or eEF2 (bottom). Inhibitors: (A) anisomycin; (C) cycloheximide; 
(D2A) didemnin 2A; (DB) didemnin B; (E) emetine; (G) G418; (H) hydrolyzable GTP; (NH) non-
hydrolyzable GTP-analog GMP-PCP; (P) puromycin; (S) sordarin. (*) Denotes the peptidyl-transferase 
center of the 60S subunit. (B–D) Effects of small-molecule inhibitors on CAT tailing. ScIVT reactions were 
prepared using rqc2Δ extracts and a lysine-free truncated mRNA substrate. After 0 min (t=0) or 20 min 
(t=20) of translation, reactions were supplemented with either protein storage buffer (–) or purified Rqc2p 
at 670 nM final concentration (+) and the indicated inhibitor(s). Indicated time points (“Time (min)”) were 
analyzed by SDS-PAGE and immunoblotting. Additional t=0 controls for the remaining inhibitors can be 
found in Figure 1-S2. 
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Figure 1-3. S. cerevisiae in vitro translation recapitulates Ltn1p-mediated ubiquitination.  
 (A) Effects of adding exogenous ubiquitin to ScIVT reactions. ScIVT reactions conducted in WT 
extracts with lysine-containing (+Lys) or lysine-free (–Lys) truncated mRNA were supplemented with the 
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indicated concentrations of recombinant ubiquitin, incubated for 60 minutes, and then analyzed by SDS-
PAGE and immunoblotting. Dashed line indicates where intervening lanes were removed for clarity. (B) 
Analysis of high-molecular-weight smears. RNase A/T1 and TEV protease treatment of ScIVT reactions 
programmed with lysine-containing truncated mRNA encoding a TEV cleavage site (TCS) in WT extracts 
supplemented with 100 µM recombinant ubiquitin. Translation was halted after 60 minutes by addition of 
20 mM EDTA, after which reactions were treated without (–) or with (+) TEV and/or RNase A/T1 for 60 
minutes, and then analyzed by SDS-PAGE and immunoblotting. Note that due to long incubations (120 
mins), very little peptidyl–tRNA persists in these reactions. (C) Isolation and detection of ubiquitinated 
ScIVT products. ScIVT reactions were conducted with 1.2 µg of truncated mRNA (3xHA-10xHis-NanoLuc, 
with or without lysines or His tag as indicated) in extracts prepared from strains of the indicated 
genotypes and supplemented with 10 µM recombinant Myc-ubiquitin. For input samples (bottom panels), 
one-third of the ScIVT reaction was quenched with 2X Laemmli Sample Buffer. For Ni-NTA-purified 
samples (top panels), two-thirds of the ScIVT reaction was quenched with 6 M guanidine-HCl. For SDS-
PAGE, 30% of input samples and 100% of Ni-NTA-purified samples were separated on 12% NuPAGE 
gels and translation products were visualized by immunoblotting with antibodies indicated at left. Dashed 
lines indicate where intervening lanes were removed for clarity. 
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Figure 1-4. Rqc1p and CAT tailing contribute to Ltn1p-dependent ubiquitination. 
 (A–C) Genetic analysis of RQC-mediated ubiquitination in ScIVT. ScIVT reactions were prepared 
using extracts from strains of the indicated genotype, a lysine-containing truncated mRNA substrate, 
ubiquitin storage buffer (–) or 100 µM recombinant ubiquitin (+), and either protein storage buffer (–) or 
the indicated purified proteins (+): Ltn1p at 130 nM, Rqc1p at 70 nM, and Rqc2p at 420 nM final 
concentration. (D) ScIVT reactions were conducted using rqc2Δ extracts, a lysine-free or lysine-
containing truncated mRNA substrate, and 100 µM exogenous ubiquitin. After 0 min (t=0) or 30 min (t=30) 
of translation, all reactions were supplemented with an equal volume of ‘mock ScIVT’ (i.e., without mRNA) 
containing 1.34 µM purified Rqc2p, 100 µM exogenous ubiquitin, and the indicated inhibitor(s). Indicated 
time points (“Time (min)”) were analyzed by SDS-PAGE and immunoblotting. ‘Long’ and ‘Short’ refer to 
exposure times of the blots. 
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Figure 1-5. CAT tailing alters the availability of lysine residues for Ltn1p-mediated ubiquitination. 
 (A) Schematic of reporter mRNAs encoding RQC substrates with 0–7 lysine residues (white lines) 
at different positions. Approximately 30–60 residues can be buried in the ribosome exit tunnel (yellow 
gradient). (B) Isolation and detection of ubiquitinated ScIVT products. ScIVT reactions were conducted 
with 1.2 µg of truncated mRNA in extracts prepared from strains of the indicated genotypes and 
supplemented with 100 µM recombinant Myc-ubiquitin. For input samples, one-third of the ScIVT reaction 
was quenched with 2x Laemmli Sample Buffer. For immunoprecipitation samples, two-thirds of the ScIVT 
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reaction was quenched with 6 M guanidine-HCl. For SDS-PAGE, 30% of input samples and 100% of 
immunoprecipitated samples were loaded onto 12% NuPAGE gels and translation products were 
visualized by immunoblotting. Dashed lines indicate that lanes were removed from the original image. (C) 
Computational analysis of the fraction of potential nascent polypeptides across the yeast proteome that 
encode a lysine in or around the ribosome exit tunnel. 
  
	 45 
 	
Figure 1-6. Model for CAT tailing and ubiquitination of stalled nascent chains.  
 When an 80S ribosome stalls during translation, splitting factors recognize the stalled translation 
complex to facilitate dissociation of the 40S subunit and mRNA. Ltn1p, Rqc2p, and Rqc1p (unknown 
location indicated by "?") bind the resulting 60S:peptidyl–tRNA complex. Together with the peptidyl-
transferase center of the 60S subunit, Rqc2p facilitates elongation of the stalled nascent chain with a CAT 
tail by recruiting alanine- and threonine-charged tRNAs to the A site. If the nascent chain contains a 
lysine residue (red circle) located within the vicinity of the Ltn1p RING domain (or potentially hidden inside 
the ribosome exit tunnel), CAT tailing and Rqc1p enhance or facilitate Ltn1p-mediated ubiquitination of 
the nascent chain, respectively, for subsequent proteasomal degradation (green box). If the nascent 
chain does not contain any lysine residues (or contains lysine residues that are too distant from the Ltn1p 
RING domain), CAT tails may promote aggregation of incompletely synthesized proteins (red box). In 
both instances, Rqc2p activity promotes hydrolysis of the peptidyl–tRNA linkage and liberation from the 
60S subunit. 
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Figure 1-S1. Purified wild-type and mutant Rqc2p.  
 C-terminal polyhistidine-tagged Rqc2p (WT and D98A mutant) were purified as described in 
Materials and methods and analyzed by SDS-PAGE and Coomassie staining. 1/10th volume of the 
corresponding purified protein was added to ScIVT reactions.  
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Figure 1-S2. Inhibitors and purified Rqc2p used to dissect the mechanism of CAT-tail synthesis.  
 (A) Effects of small-molecule inhibitors on translation. ScIVT reactions were prepared using WT 
extracts and a truncated mRNA substrate, supplemented without (–) or with (+) the indicated inhibitors 
after 0 min (t=0) of translation, and analyzed by SDS-PAGE and immunoblotting. Inhibitors: (A) 
anisomycin; (C) cycloheximide; (D2A) didemnin 2A; (DB) didemnin B; (E) emetine; (G) G418; (S) 
sordarin. Dashed lines indicate where intervening lanes were removed for clarity. (B) C-terminal 
polyhistidine-tagged Rqc2p was purified as described in Materials and methods and analyzed by SDS-
PAGE and Coomassie staining. 1/10th volume of purified protein was added to ScIVT reactions. Note that 
this stock of protein was expressed and purified independently from the stock in Figure 1-S1. 
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Figure 1-S3. Purified Ltn1p and Rqc1p. 
 C-terminal polyhistidine-tagged Ltn1p (WT and W1542E mutant) and Rqc1p were purified as 
described in Materials and methods and analyzed by SDS-PAGE and Coomassie staining. 1/10th volume 
of the corresponding purified protein was added to ScIVT reactions. 
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Figure 1-S4. Impact of excess Ltn1p on ubiquitination in rqc1Δ extracts. 
 ScIVT reactions were conducted as in Figure 1-4A to 1-4C except that 100 µM exogenous 
ubiquitin was present in all reactions.  
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Figure 1-S5. Impact of CAT-tailing inhibition on ubiquitination. 
 ScIVT reactions were conducted as in Figure 1-4D, except all reactions were performed with 
lysine-containing mRNA and ‘mock ScIVT’ containing either protein storage buffer (–) or 1.34 µM purified 
Rqc2p (+). 
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Figure 1-S6. CAT tailing exposes lysines to the Ltn1p RING domain for ubiquitination and 
subsequent degradation. 
 (A) Schematic of reporter mRNAs encoding RQC substrates with 0–7 lysines (white lines) at 
different positions (reporters H-M) and control substrates (reporters F-G). Approximately 30–60 residues 
can be buried in the ribosome exit tunnel (yellow gradient)—i.e.: Reporters F, H, K and L, M encode 
lysines located just outside or inside of the ribosome exit tunnel, respectively. (B) Effects of Rqc2p-
dependent polypeptide extensions on ubiquitination in vitro. ScIVT reactions were conducted with extracts 
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prepared from strains of the indicated genotypes and supplemented with 100uM ubiquitin. The top panel 
was exposed longer to amplify detection of ubiquitinated species. Dashed lines indicate that lanes were 
removed from the original image. (C) Effects of CAT tailing on steady-state protein levels in vivo. (′) 
Denotes in vivo equivalent of in vitro reporters. RQC reporters encoding different lysine positions and an 
R12 ribosome-stalling sequence were transformed into strains of the indicated genotypes. Proteins were 
extracted from mid-log-phase cultures and analyzed for HA-tagged proteins by immunoblotting. (*) 
Denotes a reporter product generated from read-through of the R12 stalling sequence and (**) denotes 
an uncleaved product generated due to inefficient 2A activity and read-through of the R12 stalling 
sequence (refer to Materials and Methods). 
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Table 1-S1. S. cerevisiae strains used in this study.  
 The names, genetic backgrounds, and protein expression plasmids of the strains 
generated and used in this study are listed in this table.  
 
Strain  Background Plasmid  
yBAO2112 BY4741 
 yBAO2116 BY4741 ltn1Δ::ura3 
 yBAO2117 BY4741 rqc1Δ::ura3 
 yBAO2118 BY4741 rqc2Δ::ura3 
 yBAO2125 BY4741 hbs1Δ::ura3 
 yBAO2126 BY4741 dom34Δ::ura3 
 yBAO2128 BY4741 Rqc2p(D98A) 
 yBAO2142 W303 Δbar1 lys2::HisG pep4::KanMX pGAL1-Rqc2p-10xHis, HIS3 marker  
yBAO2633 W303 Δbar1 lys2::HisG pep4::KanMX pGAL1-Rqc2p(D98A)-10xHis, HIS3 marker  
yBAO2634 W303 Δbar1 lys2::HisG pep4::KanMX pGAL1-Ltn1p-10xHis, HIS3 marker  
yBAO2635 W303 Δbar1 lys2::HisG pep4::KanMX pGAL1-Ltn1p(W1542E)-10xHis, HIS3 marker 
yBAO2636 W303 Δbar1 lys2::HisG pep4::KanMX pGAL1-Rqc1p-10xHis, HIS3 marker  
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Table 1-S2. DNA sequences of the mRNAs used in this study. 
 T7 promoter is underlined, 5'- and 3'-UTRs (if any) are in bold, TEV cleavage site (TCS) is in 
lower case. 
 
mRNA Sequence 5′ - 3′ Length (bp) 
Full-length 
3xHA-NL 
(without 
lysines): 
TAATACGACTCACTATAGGGAGACCCAAGCTAGCTAGCGTTTAAACTTAAGCTAGGTACCGAGACCATGGCCGTTTA
CCCATACGATGTTCCTGACTATGCGGGCTATCCCTATGACGTCCCGGACTATGCAGGCTCCTATCCATATGACGTTCC
AGATTACGCTGGATCTGGCGTCTTCACACTCGAAGATTTCGTTGGGGACTGGCGACAGACAGCCGGCTACAACCTGG
ACCAAGTCCTTGAACAGGGAGGTGTGTCCAGTTTGTTTCAGAATCTCGGGGTGTCCGTAACTCCGATCCAAAGGATTG
TCCTGAGCGGTGAAAATGGGCTGCGGATCGACATCCATGTCATCATCCCGTATGAAGGTCTGAGCGGCGACCAAATG
GGCCAGATCGAAAGGATTTTTAGAGTGGTGTACCCTGTGGATGATCATCACTTTCGCGTGATCCTGCACTATGGCACA
CTGGTAATCGACGGGGTTACGCCGAACATGATCGACTATTTCGGACGGCCGTATGAAGGCATCGCCGTGTTCGACGG
CAGACGCATCACTGTAACAGGGACCCTGTGGAACGGCAACAGGATTATCGACGAGCGCCTGATCAACCCCGACGGCT
CCCTGCTGTTCCGAGTAACCATCAACGGAGTGACCGGCTGGCGGCTGTGCGAACGCATTCTGGCGTAAACTAGTCCA
GTGTGGTGGAATTCTGCAGATATCCAGCACAGTGGCGGCCGCTCGAG 
743 
Truncated 
3xHA-NL 
(without 
lysines): 
TAATACGACTCACTATAGGGAGACCCAAGCTAGCTAGCGTTTAAACTTAAGCTAGGTACCGAGACCATGGCCGTTTA
CCCATACGATGTTCCTGACTATGCGGGCTATCCCTATGACGTCCCGGACTATGCAGGCTCCTATCCATATGACGTTCC
AGATTACGCTGGATCTGGCGTCTTCACACTCGAAGATTTCGTTGGGGACTGGCGACAGACAGCCGGCTACAACCTGG
ACCAAGTCCTTGAACAGGGAGGTGTGTCCAGTTTGTTTCAGAATCTCGGGGTGTCCGTAACTCCGATCCAAAGGATTG
TCCTGAGCGGTGAAAATGGGCTGCGGATCGACATCCATGTCATCATCCCGTATGAAGGTCTGAGCGGCGACCAAATG
GGCCAGATCGAAAGGATTTTTAGAGTGGTGTACCCTGTGGATGATCATCACTTTCGCGTGATCCTGCACTATGGCACA
CTGGTAATCGACGGGGTTACGCCGAACATGATCGACTATTTCGGACGGCCGTATGAAGGCATCGCCGTGTTCGACGG
CAGACGCATCACTGTAACAGGGACCCTGTGGAACGGCAACAGGATTATCGACGAGCGCCTGATCAACCCCGACGGCT
CCCTGCTGTTCCGAGTAACCATCAACGGAGTGACCGGCTGGCGGCTGTGCGAACGCATTCTGGCGGTT 
687 
Truncated 
3xHA-NL 
(with 
lysines):  
TAATACGACTCACTATAGGGAGACCCAAGCTAGCTAGCGTTTAAACTTAAGCTAGGTACCGAGACCATGGCCGTTTA
CCCATACGATGTTCCTGACTATGCGGGCTATCCCTATGACGTCCCGGACTATGCAGGCTCCTATCCATATGACGTTCC
AGATTACGCTGGATCTGGCGTCTTCACACTCGAAGATTTCGTTGGGGACTGGCGACAGACAGCCGGCTACAACCTGG
ACCAAGTCCTTGAACAGGGAGGTGTGTCCAGTTTGTTTCAGAATCTCGGGGTGTCCGTAACTCCGATCCAAAGGATTG
TCCTGAGCGGTGAAAATGGGCTGAAGATCGACATCCATGTCATCATCCCGTATGAAGGTCTGAGCGGCGACCAAATG
GGCCAGATCGAAAAAATTTTTAAGGTGGTGTACCCTGTGGATGATCATCACTTTAAGGTGATCCTGCACTATGGCACA
CTGGTAATCGACGGGGTTACGCCGAACATGATCGACTATTTCGGACGGCCGTATGAAGGCATCGCCGTGTTCGACGG
CAAAAAGATCACTGTAACAGGGACCCTGTGGAACGGCAACAAAATTATCGACGAGCGCCTGATCAACCCCGACGGCT
CCCTGCTGTTCCGAGTAACCATCAACGGAGTGACCGGCTGGCGGCTGTGCGAACGCATTCTGGCGGTT 
687 
Truncated 
3xHA-NL-
TCS 
(without 
lysines): 
TAATACGACTCACTATAGGGAGACCCAAGCTAGCTAGCGTTTAAACTTAAGCTAGGTACCGAGACCATGGCCGTTTA
CCCATACGATGTTCCTGACTATGCGGGCTATCCCTATGACGTCCCGGACTATGCAGGCTCCTATCCATATGACGTTCC
AGATTACGCTGGATCTGGCGTCTTCACACTCGAAGATTTCGTTGGGGACTGGCGACAGACAGCCGGCTACAACCTGG
ACCAAGTCCTTGAACAGGGAGGTGTGTCCAGTTTGTTTCAGAATCTCGGGGTGTCCGTAACTCCGATCCAAAGGATTG
TCCTGAGCGGTGAAAATGGGCTGCGGATCGACATCCATGTCATCATCCCGTATGAAGGTCTGAGCGGCGACCAAATG
GGCCAGATCGAAAGGATTTTTAGAGTGGTGTACCCTGTGGATGATCATCACTTTCGCGTGATCCTGCACTATGGCACA
CTGGTAATCGACGGGGTTACGCCGAACATGATCGACTATTTCGGACGGCCGTATGAAGGCATCGCCGTGTTCGACGG
CAGACGCATCACTGTAACAGGGACCCTGTGGAACGGCAACAGGATTATCGACGAGCGCCTGATCAACCCCGACGGCT
CCCTGCTGTTCCGAGTAACCATCAACGGAGTGACCGGCTGGCGGCTGTGCGAACGCATTCTGGCGggaggttcaggttcagg
tgaaaatttgtattttcaatctGTT 
726 
Truncated 
3xHA-NL-
TCS (with 
lysines): 
TAATACGACTCACTATAGGGAGACCCAAGCTAGCTAGCGTTTAAACTTAAGCTAGGTACCGAGACCATGGCCGTTTA
CCCATACGATGTTCCTGACTATGCGGGCTATCCCTATGACGTCCCGGACTATGCAGGCTCCTATCCATATGACGTTCC
AGATTACGCTGGATCTGGCGTCTTCACACTCGAAGATTTCGTTGGGGACTGGCGACAGACAGCCGGCTACAACCTGG
ACCAAGTCCTTGAACAGGGAGGTGTGTCCAGTTTGTTTCAGAATCTCGGGGTGTCCGTAACTCCGATCCAAAGGATTG
TCCTGAGCGGTGAAAATGGGCTGAAGATCGACATCCATGTCATCATCCCGTATGAAGGTCTGAGCGGCGACCAAATG
GGCCAGATCGAAAAAATTTTTAAGGTGGTGTACCCTGTGGATGATCATCACTTTAAGGTGATCCTGCACTATGGCACA
CTGGTAATCGACGGGGTTACGCCGAACATGATCGACTATTTCGGACGGCCGTATGAAGGCATCGCCGTGTTCGACGG
CAAAAAGATCACTGTAACAGGGACCCTGTGGAACGGCAACAAAATTATCGACGAGCGCCTGATCAACCCCGACGGCT
CCCTGCTGTTCCGAGTAACCATCAACGGAGTGACCGGCTGGCGGCTGTGCGAACGCATTCTGGCGggaggttcaggttcagg
tgaaaatttgtattttcaatctGTT 
726 
Truncated 
3xHA-
10xHis-NL 
(without 
lysines):  
TAATACGACTCACTATAGGGAGACCCAAGCTAGCTAGCGTTTAAACTTAAGCTAGGTACCGAGACCATGGCCGTTTA
CCCATACGATGTTCCTGACTATGCGGGCTATCCCTATGACGTCCCGGACTATGCAGGCTCCTATCCATATGACGTTCC
AGATTACGCTGGATCTGGCCATCACCATCATCACCATCACCATCATCACGGATCTGGCGTCTTCACACTCGAAGATTT
CGTTGGGGACTGGCGACAGACAGCCGGCTACAACCTGGACCAAGTCCTTGAACAGGGAGGTGTGTCCAGTTTGTTTC
AGAATCTCGGGGTGTCCGTAACTCCGATCCAAAGGATTGTCCTGAGCGGTGAAAATGGGCTGCGGATCGACATCCAT
GTCATCATCCCGTATGAAGGTCTGAGCGGCGACCAAATGGGCCAGATCGAAAGGATTTTTAGAGTGGTGTACCCTGT
GGATGATCATCACTTTCGCGTGATCCTGCACTATGGCACACTGGTAATCGACGGGGTTACGCCGAACATGATCGACTA
TTTCGGACGGCCGTATGAAGGCATCGCCGTGTTCGACGGCAGACGCATCACTGTAACAGGGACCCTGTGGAACGGC
AACAGGATTATCGACGAGCGCCTGATCAACCCCGACGGCTCCCTGCTGTTCCGAGTAACCATCAACGGAGTGACCGG
CTGGCGGCTGTGCGAACGCATTCTGGCGGTT 
726 
Truncated 
3xHA-
10xHis-NL 
(with 
lysines):  
TAATACGACTCACTATAGGGAGACCCAAGCTAGCTAGCGTTTAAACTTAAGCTAGGTACCGAGACCATGGCCGTTTA
CCCATACGATGTTCCTGACTATGCGGGCTATCCCTATGACGTCCCGGACTATGCAGGCTCCTATCCATATGACGTTCC
AGATTACGCTGGATCTGGCcatCACCATCATCACCATCACCATCATCACGGATCTGGCGTCTTCACACTCGAAGATTTC
GTTGGGGACTGGCGACAGACAGCCGGCTACAACCTGGACCAAGTCCTTGAACAGGGAGGTGTGTCCAGTTTGTTTCA
GAATCTCGGGGTGTCCGTAACTCCGATCCAAAGGATTGTCCTGAGCGGTGAAAATGGGCTGAAGATCGACATCCATG
TCATCATCCCGTATGAAGGTCTGAGCGGCGACCAAATGGGCCAGATCGAAAAAATTTTTAAGGTGGTGTACCCTGTGG
ATGATCATCACTTTAAGGTGATCCTGCACTATGGCACACTGGTAATCGACGGGGTTACGCCGAACATGATCGACTATT
TCGGACGGCCGTATGAAGGCATCGCCGTGTTCGACGGCAAAAAGATCACTGTAACAGGGACCCTGTGGAACGGCAA
CAAAATTATCGACGAGCGCCTGATCAACCCCGACGGCTCCCTGCTGTTCCGAGTAACCATCAACGGAGTGACCGGCT
GGCGGCTGTGCGAACGCATTCTGGCGGTT 
726 
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ABSTRACT 
 Bacterial CRISPR-Cas systems employ RNA-guided nucleases to destroy foreign DNA. 
Bacteriophages, in turn, have evolved diverse “anti-CRISPR” proteins (Acrs) to counteract 
acquired immunity. In Listeria monocytogenes, prophages encode 2-3 distinct anti-Cas9 
proteins, with acrIIA1 always present; however, its mechanism is unknown. Here, we report that 
AcrIIA1 binds with high affinity to Cas9 via the catalytic HNH domain and, in Listeria, triggers 
Cas9 degradation. AcrIIA1 displays broad-spectrum inhibition of Type II-A and II-C Cas9s, 
including an additional highly-diverged Listeria Cas9. During lytic infection, AcrIIA1 is insufficient 
for rapid Cas9 inactivation, thus phages require an additional “partner” Acr that rapidly blocks 
Cas9-DNA-binding. The AcrIIA1 N-terminal domain (AcrIIA1NTD) is dispensable for anti-CRISPR 
activity; instead it is required for optimal phage replication through direct transcriptional 
repression of the anti-CRISPR locus. AcrIIA1NTD is widespread amongst Firmicutes, can repress 
anti-CRISPR deployment by other phages, and has been co-opted by hosts potentially as an 
“anti-anti-CRISPR.” In summary, Listeria phages utilize narrow-spectrum inhibitors of DNA 
binding to rapidly inactivate Cas9 in lytic growth and the broad-spectrum AcrIIA1 to stimulate 
Cas9 degradation for protection of the Listeria genome in lysogeny. 
  
	 58 
INTRODUCTION 
 All cells must combat viral infections to survive. Bacteria have evolved innate and 
adaptive defense mechanisms against bacterial viruses (phages), which constantly pose a risk 
of infection. One such defense mechanism is CRISPR-Cas, a common and diverse adaptive 
immune system in prokaryotes that encompasses two distinct classes and six types (I-VI) 
(Koonin et al., 2017; Makarova et al., 2015). The CRISPR array maintains a genetic record of 
past viral infections with phage DNA fragments (spacers) retained between clustered regularly 
interspaced short palindromic repeats (CRISPR) (Mojica et al., 2005). These phage-derived 
spacers are transcribed into CRISPR RNAs (crRNAs) that complex with Cas nucleases to guide 
the sequence-specific destruction of invading nucleic acids (Brouns et al., 2008; Garneau et al., 
2010). The CRISPR-associated (cas) genes typically neighbor the CRISPR array and encode 
proteins that facilitate spacer acquisition into the CRISPR array (Nuñez et al., 2014; Yosef et al., 
2012), generate mature crRNAs (Deltcheva et al., 2011; Haurwitz et al., 2010), and cleave 
invading genomes (Garneau et al., 2010).   
 To counteract bacterial immunity, phages have evolved multiple mechanisms of 
CRISPR-Cas evasion (Borges et al., 2017). Phage-encoded anti-CRISPR proteins that directly 
inhibit type I-C, I-D, I-E, I-F, II-A, II-C, and V-A CRISPR-Cas systems have been identified 
(Hwang and Maxwell, 2019; Trasanidou et al., 2019). These anti-CRISPRs have distinct protein 
sequences, structures, and mechanisms of inactivation. Some anti-CRISPRs block CRISPR-
Cas target DNA binding by steric occlusion and DNA mimicry (Bondy-Denomy et al., 2015; 
Dong et al., 2017; Jiang et al., 2019; Liu et al., 2019; Shin et al., 2017; Yang and Patel, 2017), 
guide-RNA loading interference (Thavalingam et al., 2019; Zhu et al., 2019), and effector 
dimerization (Fuchsbauer et al., 2019; Harrington et al., 2017; Zhu et al., 2019). Other anti-
CRISPRs prevent DNA cleavage by interacting with the catalytic domain of Cas nucleases 
(Bondy-Denomy et al., 2015; Harrington et al., 2017). Anti-CRISPRs that inactivate Type II 
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CRISPR-Cas systems, which are widely utilized for genome editing applications, have been 
extensively characterized in biochemical and heterologous cell-based systems (Bondy-Denomy, 
2018; Yao et al., 2018). However, few studies have examined anti-CRISPR functions in the 
natural context of phage-bacteria warfare (Hynes et al., 2017, 2018). 
 In the lytic cycle, phage replication causes host cell lysis, whereas in lysogeny, 
temperate phages integrate into the bacterial chromosome and become prophages. The 
bacterial host and prophage replicate together during lysogeny and prophages can contribute 
novel genes that provide fitness benefits or even serve as regulatory switches (Argov et al., 
2017; Bondy-Denomy et al., 2016; Borges et al., 2017; Chen et al., 2005; Feiner et al., 2015). In 
Listeria monocytogenes, some prophages employ “active lysogeny” during mammalian cell 
infection, wherein temporary prophage excision from the bacterial chromosome allows 
expression of the comK gene required for Listeria replication in macrophages (Rabinovich et al., 
2012). Prophages also inactivate CRISPR-Cas in L. monocytogenes through the expression of 
anti-CRISPR proteins (Rauch et al., 2017). In lysogens with CRISPR arrays encoding spacers 
that target the prophage (i.e. self-targeting), anti-CRISPRs are essential for host and prophage 
survival. Whether anti-CRISPRs play distinct roles during lysogeny or lytic growth when 
expressed by temperate phages is unknown.  
 Here, we show that the Listeria phage protein AcrIIA1 selectively triggers degradation of 
catalytically active Cas9, through a direct interaction between the AcrIIA1CTD (C-terminal 
domain) unstructured loop and Cas9 HNH domain. AcrIIA1 is sufficient to stabilize CRISPR-
targeted prophages, but is ineffective during lytic replication. This inactivity necessitates the co-
existence of AcrIIA1 with an anti-CRISPR (e.g. AcrIIA2, AcrIIA4, or AcrIIA12, identified here) 
that rapidly blocks Cas9 during lytic infection. While highly conserved across AcrIIA1 homologs, 
the AcrIIA1NTD (N-terminal domain) is completely dispensable for anti-CRISPR activity and is 
instead a crucial repressor of acr locus transcription, a requirement for optimal phage fitness.  
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RESULTS 
AcrIIA1 interacts with Cas9 and triggers its degradation 
 To determine the AcrIIA1 mechanism of action, we first attempted to immunoprecipitate 
Cas9 from L. monocytogenes (Lmo10403s) strains, where AcrIIA1 was expressed from one of 
three prophages (ΦA006, ΦA118, and ΦJ0161a). Surprisingly, upon immunoblotting for Cas9 
protein, we observed highly reduced Cas9 levels in these lysogens (Figure 2-1A). 
Transcriptional and translational reporters revealed that transcript levels were unaffected, while 
the protein reporter levels decreased by ~70% (Figure 2-1A). RT-qPCR experiments confirmed 
Cas9 mRNA levels were unaffected in each lysogen (Figure 2-S1A). AcrIIA1 alone, but not 
AcrIIA4, was sufficient to mediate decreased Cas9 levels in both reporter and western blot 
assays (Figure 2-1B). The well-studied orthologue, SpyCas9 (53% amino acid identity to 
LmoCas9), displayed the same post-transcriptional AcrIIA1-dependent loss of Cas9 when 
introduced into L. monocytogenes (Figure 2-1B).  
 To assay for a direct interaction in vitro, AcrIIA1 and SpyCas9 were purified (LmoCas9 
was insoluble). AcrIIA1 and the SpyCas9-gRNA complex interacted with high affinity (KD = 23 ± 
15 nM) by microscale thermophoresis (MST), comparable to AcrIIA2b.3 (KD = 20 ± 11 nM), a 
well-characterized Cas9-interactor (Jiang et al., 2019; Liu et al., 2019) (Figure 2-1C). 
Additionally, AcrIIA1 interacted with ApoCas9, unlike AcrIIA2b.3, suggesting a unique binding 
mechanism (Figure 2-S1B). Neither binding event was sufficient to degrade Cas9 in vitro, nor 
was the protein destabilized when subjected to limited proteolysis (Figure 2-S1C). We therefore 
considered whether the cellular environment of L. monocytogenes stimulates Cas9 degradation 
when bound by AcrIIA1. Indeed, we observed an accelerated decay of SpyCas9 protein upon 
induction of AcrIIA1 compared to treatment with a translation inhibitor, gentamicin (Figures 2-1D 
and 2-S1D). In contrast, SpyCas9 protein increased over time when AcrIIA1 was not induced; 
similar to strains expressing AcrIIA4 or lacking an anti-CRISPR (Figures 2-1D and 2-S1D). 
	 61 
 However, we paradoxically observed that AcrIIA1 did not inhibit catalytically-dead Cas9 
(dCas9) in a CRISPRi assay using Lmo- or Spy- dCas9 engineered to repress RFP expression 
(Figures 2-1E and 2-S1F), but did inhibit active Cas9 in an isogenic self-targeting strain (Figure 
2-1F). Consistent with these findings, lysogens expressing AcrIIA1 or AcrIIA4 alone or together 
also revealed no significant decrease in dCas9 levels (Figures 2-1G and 2-S1H), whereas 
active Cas9 protein diminished by ~70% in all AcrIIA1-expressing lysogens (Figures 2-1G, 2-
S1G and 2-S1H). Therefore, AcrIIA1 has a mechanism to detect catalytically active Cas9 
protein and trigger its degradation. 
 Given the discrepant outcomes between Cas9 and dCas9, the ability of AcrIIA1 to bind 
these proteins in vitro was assessed. AcrIIA1 interacted with dCas9-gRNA ~40-fold weaker (KD 
= 905 ± 874 nM) than with Cas9-gRNA (Figures 2-1C, 2-1H and 2-S1I). Only two residues differ 
between catalytically active Cas9 and dCas9 (D10A and H840A). AcrIIA1 binding to 
Cas9(D10A) (KD = ~38 nM) was similar to wild-type Cas9 (KD = ~23, Figure 2-1), whereas 
binding to Cas9(H840A) was ~80-fold weaker (KD = 2 ± 4 µM) (Figures 2-1H and 2-S1I). 
AcrIIA2b.3, which binds the PAM-interacting domain, displayed no difference in binding affinity 
to the four Cas9 variants (KD = 18 – 38 nM) (Figures 2-1H and 2-S1I). Therefore, we conclude 
that AcrIIA1 triggers the degradation of catalytically active Cas9 in L. monocytogenes through a 
direct interaction with the Cas9 HNH domain (where H840 resides). 
AcrIIA1 protects CRISPR-targeted prophages but fails during lytic replication 
 Given that AcrIIA1 triggers Cas9 degradation, a mechanism not previously observed for 
any anti-CRISPR, we sought to determine when this activity manifests in the phage life cycle. 
Isogenic ΦA006 phages were engineered to encode no anti-CRISPR, acrIIA1, acrIIA4, or 
acrIIA1 and acrIIA4 together, and assessed along with wild-type (WT) phages, during lytic and 
lysogenic infection. When infecting Lmo10403s expressing Cas9 and a native ΦA006-targeting 
spacer sequence, phages encoding only acrIIA1 surprisingly failed to replicate, similar to a ∆acr 
phage (efficiency of plaquing, EOP ≤ 3x10-5, Figures 2-2A and 2-S2A). Phages encoding 
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acrIIA4 replicated well (EOP = 0.1 – 0.7, depending on acrIIA4 expression strength), similar to 
WT ΦA006 (EOP ≥ 0.7), with no added benefit derived from acrIIA1 (Figures 2-2A and 2-S2A). 
In contrast, during lysogeny, ΦA006 prophages encoding acrIIA1 completely prevented self-
targeting upon Cas9 induction, whereas lysogens lacking an anti-CRISPR (∆acr) died (Figure 2-
2B). The remarkable difference in AcrIIA1 efficacy during lytic and lysogenic growth bolsters a 
conclusion that the Cas9 degradative mechanism is optimal for the lysogenic lifestyle, but not 
fast enough for inactivation during lytic replication. 
 Given the inability of AcrIIA1 to inhibit Cas9 during lytic infection, phages may need 
additional Cas9 inhibitors. Indeed, in 119 Listeria prophage genomes analyzed, 77% encode 
acrIIA1 with at least one additional acrIIA gene (i.e. acrIIA2-A4), 13% possess acrIIA1 without a 
known acrIIA neighbor (including WT ΦA006), and 10% encode orfD (a distant acrIIA1 
orthologue), along with other uncharacterized ORFs (Rauch et al., 2017). The WT ΦA006 
phage, which has acrIIA1 and no other known acr, replicated far better (EOP ≥ 0.7) than a 
phage encoding acrIIA1 alone, suggesting an additional Cas9 inhibitor in this phage (Figures 2-
2A and 2-S2A). Engineered phages encoding the gene adjacent to acrIIA1 restored phage lytic 
replication (EOP ≥ 0.5) and revealed a new anti-CRISPR, AcrIIA12, which also inhibited Lmo 
(but not Spy) dCas9-based CRISPRi (Figures 2-2A, 2-S2A and 2-S2B). Notably, we observed 
the presence of acrIIA12 in every acr locus previously reported to encode only acrIIA1, 
indicating that prophages do not encode acrIIA1 alone. Therefore, Listeria prophages most 
commonly encode acrIIA1, which triggers Cas9 degradation to ensure stable lysogeny, in 
combination with a Cas9 interactor that blocks DNA binding (AcrIIA2, AcrIIA4, or AcrIIA12) for 
successful lytic replication. 
AcrIIA1 utilizes an unstructured C-terminal loop to inactivate Cas9 
 The AcrIIA1 crystal structure revealed a two-domain architecture, with a helix-turn-helix 
(HTH)-containing AcrIIA1NTD similar to known transcriptional repressors and an extended 
AcrIIA1CTD of unknown function (Ka et al., 2018). Surprisingly, the AcrIIA1CTD was sufficient for 
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anti-CRISPR function, protection from self-targeting, and triggering Cas9 protein degradation, 
while the AcrIIA1NTD displayed no evidence of Cas9 regulation (Figures 2-S2C and 2-S2D). To 
identify AcrIIA1 residues required for anti-CRISPR function, we conducted multi-sequence 
alignments and used our previously developed heterologous P. aeruginosa anti-SpyCas9 
screening platform (Jiang et al., 2019). AcrIIA1 homologs were identified in mobile genetic 
elements of Listeria, Enterococcus, Lactobacillus, and Leuconostoc species, ranging from 22% 
to 77% protein sequence identity (Figures 2-2C and 2-S4D). Homology was driven by obvious 
sequence similarity in the NTD, with CTD conservation in only a subset of proteins. AcrIIA1 
homologs with conserved CTDs displayed anti-SpyCas9 activity (except AcrIIA1LMO10), whereas 
the three proteins with highly diverged CTDs (including orfD) did not (Figures 2-2D and 2-S3A). 
Alanine scanning mutagenesis of the conserved amino acids present in AcrIIA1 homologs 
identified a stretch of aromatic and charged residues in an unstructured region of the AcrIIA1CTD 
(P112 to R117) that were required for complete anti-CRISPR activity (Figures 2-2E and 2-S3A). 
Expression levels of each mutant protein were unperturbed relative to WT AcrIIA1 (Figure 2-
S3B). The F115A mutation completely abolished anti-CRISPR function (Figures 2-2E and 2-
S3A) and the interaction with Cas9 (Figures 2-2F, 2-S2F and 2-S2G). In Listeria, 
AcrIIA1(F115A) and AcrIIA1(T114A/F115A) mutants failed to protect cells from genomic self-
targeting (Figure 2-S2C) and these mutations either completely (T114A/F115A) or partially 
(F115A) restored Cas9 protein levels (Figure 2-S2E). 
 When verifying expression of AcrIIA1 mutants, we observed that AcrIIA1-mediated 
inhibition does not trigger Cas9 degradation in P. aeruginosa (Figure 2-S3B). Yet, similar to in 
Listeria, AcrIIA1 still displayed robust anti-CRISPR activity, inactivating Cas9 in phage-targeting 
and self-targeting experiments, while not interfering with CRISPRi (Figures 2-S3A and 2-S3C). 
Since AcrIIA1 can apparently inhibit Cas9 without causing degradation, we immunoprecipitated 
Cas9 bound to AcrIIA1 or the control AcrIIA4 from P. aeruginosa (Figures 2-2F and 2-S2F) and 
assessed DNA cleavage activity in vitro. Cas9 was functional when immunoprecipitated alone 
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but inhibited when co-purified with AcrIIA1 or AcrIIA4 (Figure 2-2G and 2-S2H). The AcrIIA1 
mutants (F115A and T114A/F115A) interacted with Cas9 very weakly (Figures 2-2F, 2-S2F and 
2-S2G) and had little impact on DNA cleavage (Figure 2-S2H). Interestingly, in vitro experiments 
with individually purified proteins revealed that AcrIIA1 is not sufficient to inhibit Cas9-mediated 
DNA cleavage (Figure 2-S2I), despite its strong binding affinity, suggesting an additional cellular 
factor is required to inactivate Cas9. This putative multi-step process may explain why inhibition 
does not manifest immediately during lytic growth. Therefore, AcrIIA1 utilizes conserved 
residues in its CTD to interact with the Cas9 HNH domain, blocking DNA cleavage and 
triggering Cas9 protein degradation in Listeria. In a foreign host potentially lacking the Cas9-
degrading pathway, DNA cleavage inhibition manifests.  
AcrIIA1 is a broad-spectrum Cas9 inhibitor  
 Given the ability of AcrIIA1 to inactivate Cas9 via recognition of a highly conserved 
catalytic residue, we assessed inhibition of diverged Cas9 orthologues. In Escherichia coli 
strains expressing Type II-A, II-B, and II-C Cas9 proteins (Figure 2-3A) targeting phage Mu, 
AcrIIA1 intermediately or completely inhibited four Type II-C (Boe, Hpa, Cje, and Geo) and two 
Type II-A (Sau and Spy) Cas9s (Figures 2-3B and 2-S3D). In contrast, AcrIIA2 only weakly 
inhibited Hpa and SpyCas9, while AcrIIA4 only inactivated SpyCas9 (Figure 2-3B). Considering 
the biological driver of broad-spectrum Cas9 inhibition by AcrIIA1, a smaller Type II-A Cas9 
(1,078 a.a.) was recently discovered in L. ivanovii (LivCas9) (Hupfeld et al., 2018) with 
similarities to other small Cas9 proteins (e.g. SauCas9) and Type II-C orthologues (Figure 2-
3A). In Listeria strains expressing the small LivCas9 variant programmed to target phage ΦP35 
or ΦA511, AcrIIA1 inhibited LivCas9 (Figures 2-3C and 2-S3E). Thus, AcrIIA1 displays broad-
spectrum activity against diverged Cas9 nucleases, whereas the well-characterized DNA 
binding inhibitors, AcrIIA2 and AcrIIA4, are much narrower in their inhibitory spectrum. This 
broad-spectrum inhibition also likely explains the utility of AcrIIA1 to phages infecting Listeria, 
where two distinct Cas9 orthologues are encountered.   
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 The robust AcrIIA1 activity observed in various heterologous hosts led us to assess 
inhibition of Cas9 gene editing in human cells. We employed a deep sequencing-based 
approach to improve the dynamic range of edit detection, in comparison to our previous GFP-
disruption assay (Rauch et al., 2017). HEK 293T cells were co-transfected with plasmids 
encoding acrIIA1, cas9, and sgRNAs targeting endogenous human sequences and editing 
efficacy was evaluated after 3 days. AcrIIA1 blocked the gene editing activity of SpyCas9 by 50-
70% and of CjeCas9, SauCas9, St3Cas9, and NmeCas9 moderately, whereas AcrIIA4 only 
inhibited SpyCas9 (Figures 2-3D and 2-S3E). Thus, AcrIIA1 inactivates diverse Cas9 
orthologues in many heterologous systems, including bacteria (L. monocytogenes, P. 
aeruginosa, E. coli), yeast (Nakamura et al., 2019), and human cells, providing a genome 
editing modulator that specifically prevents Cas9 DNA cleavage. Future work is needed to 
enhance its efficiency, however.  
acr locus repression by AcrIIA1NTD promotes general lytic growth and prophage induction 
 While interrogating the requirements for anti-CRISPR function, we observed that two 
engineered phages with deletions in their anti-CRISPR locus (ΦA006∆acr and 
ΦJ0161a∆acrIIA1-2) displayed a Cas9-independent lytic growth defect (Figure 2-4A). This 
defect was rescued by the provision of acrIIA1NTD in trans or by engineering an ΦA006 phage to 
express only the acrIIA1NTD (Figure 2-4A). Moreover, all engineered ΦA006 phages expressing 
an anti-CRISPR (e.g. acrIIA1CTD, acrIIA4, acrIIA12) without the acrIIA1NTD displayed a decrease 
in phage titer (PFU/mL) that was restored by acrIIA1NTD trans- or cis-complementation (Figure 2-
4A). The phage expressing only acrIIA1CTD (only observed fused to acrIIA1NTD in genomes) 
displayed the strongest lytic defect amongst the ΦA006 phages, while simply separating the two 
AcrIIA1 domains had no deleterious effect (Figure 2-4A). ΦJ0161a∆acrIIA1-2 had the most 
drastic lytic defect, failing to replicate unless complemented in trans with the acrIIA1NTD (Figure 
2-4A). Moreover, the ΦJ0161a∆acrIIA1-2 prophage displayed a Cas9-independent prophage 
induction deficiency, yielding 25-fold less phage during mitomycin C induction, compared to the 
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WT prophage or the acrIIA1-complemented mutant (Figure 2-4B). Attempts to efficiently induce 
ΦA006 prophages were unsuccessful, as previously observed (Loessner, 1991; Loessner et al., 
1991). Therefore, aside from acting as an anti-CRISPR, AcrIIA1 plays an important Cas9-
independent role in the phage life cycle, promoting optimal lytic replication and lysogenic 
induction. 
 AcrIIA1NTD contains an HTH motif with strong similarity to transcriptional repressors (Ka 
et al., 2018). Due to the Cas9-independent growth defects described above, we considered 
whether regulation of the anti-CRISPR locus is required. Alignments of the anti-CRISPR 
promoters of ΦA006, ΦJ0161, and ΦA118 revealed a highly conserved palindromic sequence 
(Figures 2-4C and S4A). An RFP transcriptional reporter assay showed that full-length AcrIIA1 
and AcrIIA1NTD, but not AcrIIA1CTD, repress the ΦA006 anti-CRISPR promoter (Figure 2-4E, 
left). In vitro MST binding assays confirmed that AcrIIA1 (KD = 26 ± 10 nM) or AcrIIA1NTD (KD = 
28 ± 3 nM) bind the anti-CRISPR promoter with high affinity (Figures 2-4D and 2-S4B). 
Moreover, mutagenesis of the palindromic sequence prevented AcrIIA1-mediated repression of 
the ΦA006 anti-CRISPR promoter (Figure 2-4E, right) and abolished promoter binding in vitro 
(Figure 2-4D). Alanine scanning mutagenesis of conserved residues predicted to be important 
for DNA binding and dimerization (Ka et al., 2018) identified AcrIIA1NTD residues L10, T16, and 
R48 as critical for transcriptional repression, whereas AcrIIA1CTD mutations had little effect 
(Figure 2-4F). Finally, we observed that Cas9 degradation induced by prophage-expressed 
AcrIIA1 in L. monocytogenes (Figure 2-1A) could be prevented by AcrIIA1NTD overexpression, 
due to repression of the anti-CRISPR locus (Figure 2-4G). Thus, the AcrIIA1NTD-HTH domain 
represses anti-CRISPR transcription through a highly conserved operator, which is required for 
optimal phage fitness.  
Transcriptional autoregulation is a general feature of the AcrIIA1 superfamily  
 Recent studies have reported transcriptional autoregulation of anti-CRISPR loci by HTH-
proteins in phages that infect Gram-negative Proteobacteria, as a mechanism to limit excessive 
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transcription and downstream transcriptional conflict (Birkholz et al., 2019; Stanley et al., 2019). 
To determine whether anti-CRISPR locus regulation is similarly pervasive amongst mobile 
genetic elements in the Gram-positive Firmicutes phylum, we assessed AcrIIA1 homologs for 
transcriptional repression of their predicted cognate promoters and our model ΦA006 phage 
promoter. Homologs sharing amino acid sequence identity from 21% (i.e. OrfD) to 72% with 
AcrIIA1NTD were selected from Listeria, Enterococcus, Leuconostoc, and Lactobacillus (Figure 
2-4H and 2-S4D). All AcrIIA1 homologs repressed transcription of their cognate promoters by 
42-99%, except AcrIIA1 from Lactobacillus parabuchneri, where promoter expression was 
undetectable in a foreign host (Figures 2-4H and 2-S4C). Strong repression of the model ΦA006 
promoter was seen by Listeria orthologues possessing ≥68% protein sequence identity (Figure 
2-4H). Likewise, AcrIIA1ΦA006 repressed the promoters of AcrIIA1 orthologues that repressed the 
ΦA006 promoter (Figure 2-4I). Interestingly, the AcrIIA1LMO10 homolog, which previously 
displayed no anti-CRISPR activity despite possessing 85% AcrIIA1CTD sequence identity 
(Figures 2-2D and 2-S3A), contains an AcrIIA1NTD palindromic binding site overlapping its 
protein-coding sequence. AcrIIA1LMO10 anti-CRISPR function manifested when the AcrIIA1NTD 
binding site was disrupted with silent mutations (Figure 2-S3A). Altogether, these findings 
demonstrate that the anti-CRISPR promoter-AcrIIA1NTD repressor relationship is highly 
conserved.  
Host-encoded AcrIIA1NTD blocks phage anti-CRISPR deployment 
 Given that the AcrIIA1NTD represses anti-CRISPR transcription, we wondered whether 
bacteria could co-opt this activity and manifest it in trans, inhibiting a phage from deploying its 
anti-CRISPR arsenal. We observed that ΦA006-derived phages encoding anti-CRISPRs were 
rendered vulnerable to Cas9 targeting when the host expressed anti-CRISPR-deficient AcrIIA1 
mutants or AcrIIA1NTD (Figure 2-5A). A panel of distinct anti-CRISPR-encoding phages also 
became vulnerable to Cas9 targeting when AcrIIA1NTD was expressed from a plasmid (Figure 2-
5B) or from an integrated single-copy acrIIA1NTD driven by a prophage promoter (Figure 2-S5A). 
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Each of these phages possesses complete or partial spacer matches to the Lmo10403s 
CRISPR array. In contrast, replication of the non-targeted phage, ΦJ0161a, was unperturbed 
(Figure 2-5B). This demonstrates that host or mobile elements can use this repressor as an 
“anti-anti-CRISPR” to block anti-CRISPR synthesis, which may be particularly advantageous, if 
infecting phages encode other anti-CRISPR proteins (e.g. against the Listeria Type I-B 
CRISPR-Cas system).  
 The widespread prevalence of AcrIIA1 is driven by AcrIIA1NTD, with orthologues in many 
Firmicutes including Enterococcus, Bacillus, Clostridium, and Streptococcus. The AcrIIA1NTD 
can be found either without a CTD or with a distinct CTD sequence. Diverged AcrIIA1CTDs may 
represent novel anti-CRISPRs, inhibiting CRISPR-Cas systems in their respective hosts. In 
Lactobacillus sp., for example, there are full-length prophage proteins that lacked anti-SpyCas9 
function and contain a novel AcrIIA1CTD (Figures 2-2C, 2-2D and 2-S3A). In other instances, 
core bacterial genomes encode AcrIIA1NTD orthologues that are short ~70-80 amino acid 
proteins possessing only the HTH domain. In particular, Lactobacillus delbrueckii strains contain 
an AcrIIA1NTD homolog (35% identical, 62% similar to AcrIIA1ΦA006) with key residues conserved 
(e.g. L10 and T16). Although there are no known Lactobacillus phages that express anti-
CRISPRs, this bacterial acrIIA1NTD gene may perform an “anti-anti-CRISPR” function. 
Remarkably, we observe that this AcrIIA1NTD homolog is always a genomic neighbor of either 
the Type I-E, I-C, or II-A CRISPR-Cas systems in L. delbrueckii (Figure 2-5C). This association 
is supportive of a role that enables these CRISPR-Cas systems to function by repressing the 
deployment of phage inhibitors against each system. The functions of these diverse AcrIIA1 
orthologues found in different bacteria, many of which act as transcriptional repressors (Figure 
2-4H), remain to be elucidated.  
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DISCUSSION 
 Listeria temperate phages commonly encode the multifunctional AcrIIA1 protein for 
protection against CRISPR-Cas and autorepression of anti-CRISPR transcription. The broad-
spectrum AcrIIA1 is sufficient for Cas9 inactivation during lysogeny, but a nonfunctional anti-
CRISPR during lytic growth, perhaps due to slow kinetics of Cas9 cleavage inhibition or 
degradation. Thus, AcrIIA1 always coexists with a distinct anti-Cas9 protein (e.g. AcrIIA2, 
AcrIIA4, AcrIIA12) that is much narrower in its inhibitory spectrum, but rapidly inactivates Cas9 
during lytic replication. Therefore, Listeria temperate phages have evolved multiple anti-
CRISPRs with distinct Cas9 binding sites and inactivation mechanisms because they 
synergistically grant unique advantages in each stage of the temperate phage life cycle (see 
model, Figure 2-6). While “partner” proteins AcrIIA4 and AcrIIA12 also protected CRISPR-
targeted prophages, only AcrIIA1 triggered Cas9 degradation, presumably enhancing the 
likelihood of long-term stability in lysogeny. Listeria lysogens were devoid of Cas9 even when 
acrIIA1 was co-encoded with other acrs, supporting that Cas9 degradation is the dominant 
inactivation mechanism in lysogeny. Given that Cas9 is required for selection of functional 
spacers by recognizing the correct PAM (Heler et al., 2015), eliminating this nuclease could also 
prevent acquisition of lethal self-targeting spacers.  
 Notably, this is the first report of an anti-CRISPR that reduces Cas protein levels and is 
also the first with an additional role integral to the phage life cycle. The highly conserved 
AcrIIA1NTD plays a general Cas9-independent role by autorepressing acr locus transcription to 
promote phage lytic growth and prophage induction. Engineered phages expressing the 
AcrIIA1CTD alone had a strong lytic growth defect, perhaps suggesting the AcrIIA1 domains are 
fused in nature to limit expression of an otherwise problematic anti-CRISPR. Interestingly, when 
the bacterial host expresses AcrIIA1NTD, an “anti-anti-CRISPR” activity manifests, blocking anti-
CRISPR expression from infecting or integrated phages. Thus, the importance of the conserved 
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anti-CRISPR locus repression mechanism may represent a weakness that can be exploited by 
the host through the co-opting of this anti-CRISPR regulator.  
 Many diverse Cas9 orthologues have been identified and AcrIIA1 can inhibit highly 
distinct II-A and II-C subtypes. This provides a unique advantage to Listeria phages, inhibiting a 
small LivCas9 variant (25% amino acid identity to large LmoCas9) that is also found in L. 
monocytogenes strains. LivCas9 also shares similarity with Type II-C Cas9s, likely explaining 
the biological basis of AcrIIA1 activity against the II-C subtypes. Broad-spectrum inhibition by 
AcrIIA1 is likely due to targeting the highly conserved Cas9 HNH domain catalytic site, whereas 
the DNA binding inhibitors (AcrIIA2, AcrIIA4, AcrIIA12) are far more limited. AcrIIC1 was 
similarly reported to block various Type II-C orthologues by directly binding Cas9 (Apo or gRNA-
bound) via the HNH domain (Harrington et al., 2017). Much like AcrIIA1, AcrIIC1 binds the 
NmeCas9 HNH domain with strong affinity (KD = 6.3 nM; Harrington et al., 2017), but it is a 
rather weak anti-CRISPR in comparison to the DNA binding inhibitors AcrIIC3-5, which have 
narrow inhibitory spectrums (Lee et al., 2018; Mathony et al., 2019). Therefore, although Cas9 
DNA cleavage inhibitors may tend to be weaker anti-CRISPRs, they considerably bolster the 
phage defense arsenal by targeting a highly conserved, and potentially immutable feature 
amongst bacterial Cas nucleases. Future engineering of AcrIIA1 could generate a more potent 
inhibitor, as recently achieved with AcrIIC1 (Mathony et al., 2019). Our attempt to increase anti-
CRISPR function in human cells by weakening DNA interactions (AcrIIA1(T16A) mutant, Figure 
2-3D) was only modestly successful.  
 Widespread AcrIIA1NTD conservation also raises the possibility that prophages use this 
domain to combat phage superinfection, benefitting both the prophage and host cell. Precedent 
for phage repressors acting in this manner, both in cis and in trans, is strong. For example, the 
phage lambda cI protein represses prophage lytic genes and prevents superinfection by related 
phages during lysogeny (Johnson et al., 1981). Similarly, lysogens could use AcrIIA1 to temper 
expression of the prophage anti-CRISPR locus while bolstering the activity of a second 
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CRISPR-Cas system (e.g. Type I-B, which is common in Listeria), by preventing incoming 
phages from expressing their anti-CRISPRs. Given the diversity of anti-CRISPR protein 
sequences, blocking transcription would be a much more effective strategy than inhibiting 
individual anti-CRISPRs. Lastly, the widespread nature of the AcrIIA1NTD, its fusion to distinct 
CTDs, and its shared genetic neighborhood with mechanistically distinct anti-CRISPRs, may be 
a useful marker for future acr discovery. 
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MATERIALS AND METHODS  
Microbes  
 Listeria monocytogenes strains (10403s) were cultured in brain-heart infusion (BHI) 
medium at 30°C. All Lmo strains containing pPL2oexL-Rhamnose-inducible constructs were 
cultured in Luria broth (LB) supplemented with 50-150 mM glycerol (neutral carbon source; no 
induction/repression) and 0-100 mM rhamnose (inducer) as indicated. To ensure plasmid 
maintenance in Listeria strains, BHI or LB was supplemented with tetracycline (2 µg/mL) for the 
pPL2oexL integrated construct or erythromycin (7.5 µg/mL) for pLEB579. Escherichia coli 
(DH5α, XL1Blue, NEB 10-beta, or NEB Turbo for plasmid maintenance and SM10 for 
conjugation into Listeria) and Pseudomonas aeruginosa (PAO1) were cultured in LB medium at 
37°C. To maintain plasmids, LB was supplemented with chloramphenicol (25 µg/mL) for 
pPL2oexL in E. coli, erythromycin (250 µg/mL) for pLEB579 in E. coli, gentamicin (30 µg/mL) for 
pHERD30T in E. coli and P. aeruginosa, or carbenicillin (250 µg/mL for P. aeruginosa, 100 
µg/mL for E. coli) for pMMB67HE. For maintaining pHERD30T and pMMB67HE in the same P. 
aeruginosa strain, media was supplemented with 30 µg/mL gentamicin and 100 µg/mL 
carbenicillin.  
 
Phages 
 Listeria phages A006, A118, A502, A620, J0161a, and their derivatives were all 
propagated at 30°C on acrIIA1NTD-expressing L. monocytogenes 10403sɸcure (Δcas9, 
ΔtRNAArg::pPL2oexL-acrIIA1NTD) to allow optimal lytic growth of phages lacking their own 
acrIIA1NTD. A511 was propagated on L. ivanovii WSLC 3009 at 30°C and P35 on L. 
monocytogenes Mack at 20°C. The Pseudomonas DMS3m-like phage (JBD30) was propagated 
on PAO1 at 37°C. All phages were stored in SM buffer (100 mM NaCl, 8 mM MgSO4•7H2O, 50 
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mM Tris-HCl pH 7.5, 0.01% (w/v) gelatin), supplemented with 10 mM CaCl2 for Listeria phages, 
at 4°C.  
 
Human cell lines  
 Human HEK 293T cells (ATCC) were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% heat-inactivated FBS (HI-FBS) and 1% penicillin/streptomycin. 
Media supernatant from cell cultures was analyzed monthly for the presence of mycoplasma 
using MycoAlert PLUS (Lonza). 
 
METHOD DETAILS 
Construction of isogenic ϕA006 anti-CRISPR phages  
 Isogenic ϕA006 phages encoding distinct anti-CRISPRs from the native anti-CRISPR 
locus were engineered by rebooting genomic bacteriophage DNA in L. monocytogenes L-form 
cells (EGDe strain variant Rev2) as previously described (Kilcher et al., 2018). Denoted acr 
genes (*) contain the strong ribosomal binding site (RBS) naturally associated with the first gene 
in the natural ϕA006 anti-CRISPR locus (orfA) whereas unmarked genes contain the weaker 
RBS associated with acrIIA1. 
 
Listeria phage titering 
 A mixture of 150 µl stationary Listeria culture and 3 mL molten LC top agar (10 g/L 
tryptone, 5 g/L yeast extract, 10 g/L glucose, 7.5 g/L NaCl, 10 mM CaCl2, 10 mM MgSO4, 0.5% 
agar) was poured onto a BHI plate (1.5% agar) to generate a bacterial lawn, 3 µl of phage ten-
fold serial dilutions were spotted on top, and after 24 hr incubation at 30°C, plate images were 
collected using the Gel Doc EZ Documentation system (BioRad) and Image Lab (BioRad) 
software.  
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Construction of Lmo10403s::ϕA006/ϕA118/ϕJ0161a lysogens 
 Lysogens were isolated from plaques that emerged after titering phages ϕA006, ϕA118, 
ϕJ0161a, and their derivatives on a lawn of Lmo10403sɸcureΔcas9 (see “Listeria phage 
titering”). Lysogeny was confirmed by prophage induction with mitomycin C (0.5 µg/mL) 
treatment as previously described (Estela et al., 1992) and by PCR amplification and Sanger 
sequencing of the phage anti-CRISPR locus. All Lmo10403s strains containing prophages were 
lysogenized and verified prior to introducing additional constructs (integrated pPL2oexL or 
episomal pLEB579).  
 
Construction of L. monocytogenes and P. aeruginosa strains  
 DNA fragments were PCR-amplified from genomic, plasmid, or synthesized DNA and 
cloned by Gibson Assembly into Listeria plasmids: episomal pLEB579 (Beasley et al., 2004) or 
the pPL2oexL single-copy integrating plasmid derived from pPL2 (Lauer et al., 2002) or P. 
aeruginosa plasmids: pMMB67HE or pHERD30T. To generate all Listeria strains, pPL2oexL 
plasmids were conjugated (Lauer et al., 2002; Simon et al., 1983) and pLEB579 plasmids were 
electroporated (Hupfeld et al., 2018; Park and Stewart, 1990) into Lmo10403s. For all 
Pseudomonas strains, plasmids were electroporated into PAO1 (Choi et al., 2006). 
 
Listeria protein samples for immunoblotting  
 Saturated overnight cultures of Lmo10403s strains overexpressing FLAG-tagged Cas9 
(Δcas9, ΔtRNAArg::pPL2oexL-LmoCas9-6xHis-FLAG) were diluted 1:10 in BHI with appropriate 
antibiotic selection (see “microbes”), grown to log phase (OD600 0.2-0.6), harvested by 
centrifugation at 8000 g for 5 min at 4°C, and lysed by bead-beating or lysozyme treatment. For 
bead-beating: 4 OD600 units of each culture were harvested, cell pellets were resuspended in 
500 µl ice cold lysis buffer (50 mM Tris-HCl pH 8.0, 650 mM NaCl, 10 mM MgCl2, 10% glycerol, 
1x cOmplete mini EDTA-free protease inhibitor cocktail [Roche]), combined with ~150 µl 0.1 mm 
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glass beads, and vortexed for 1 hr at 4°C. Cell debris was cleared by centrifugation at 21000 g 
for 5 min at 4°C and supernatant was mixed with one-third volume 4X Laemmli Sample Buffer 
(Bio-Rad). For lysozyme lysis: 1.6 OD600 units were harvested, cell pellets were resuspended in 
200 µl of TE buffer supplemented with 2.5 mg/mL lysozyme and 1x cOmplete mini EDTA-free 
protease inhibitor cocktail (Roche), samples were incubated at 37°C for 30 min, quenched with 
one-third volume of 4X Laemmli Sample Buffer (Bio-Rad), and boiled for 5 min at 95°C.  
 
Immunoblotting 
 Protein samples were separated by SDS-PAGE using 4-20% Mini-PROTEAN TGX gels 
(Bio-Rad) and transferred in 1X Tris/Glycine Buffer onto 0.22 micron PVDF membrane (Bio-
Rad). Blots were probed with the following antibodies diluted 1:5000 in 1X TBS-T containing 5% 
nonfat dry milk: rabbit anti-FLAG (Sigma-Aldrich Cat# F7425, RRID:AB_439687), mouse anti-
FLAG (Sigma-Aldrich Cat# F1804, RRID:AB_262044), mouse anti-Myc (Cell Signaling 
Technology Cat# 2276, RRID:AB_331783), rabbit anti-GST (Cell Signaling Technology Cat# 
2625, RRID:AB_490796), mouse anti-E.coli RNA polymerase β (BioLegend Cat# 663903, 
RRID:AB_2564524), HRP-conjugated goat anti-Rabbit IgG (Bio-Rad Cat# 170-6515, 
RRID:AB_11125142), and HRP-conjugated goat anti-mouse IgG (Santa Cruz Biotechnology 
Cat# sc-2005, RRID:AB_631736). Blots were developed using Clarity ECL Western Blotting 
Substrate (Bio-Rad) and chemiluminescence was detected on an Azure c600 Imager (Azure 
Biosystems).  
 
Bacterial growth (OD600) and fluorescence (RFU) measurements  
 Saturated overnight cultures were diluted 1:100 in 150 µl BHI or LB media with 
appropriate antibiotic selection (see “microbes”) in a 96-well special optics microplate (Corning). 
Listeria cells were incubated at 30°C and Pseudomonas at 37°C with continuous double-orbital 
rotation for 16-48 hr in the Synergy H1 Hybrid Multi-Mode Reader (BioTeK) and measurements 
	 78 
of OD600 and mCherry (excitation 570 nm, emission 610 nm) or RFP (excitation 555 nm, 
emission 610 nm) relative fluorescence units (RFU) recorded every 5 min with the Gen5 
(BioTek) software. For bacterial growth curves, data are displayed as the mean OD600 of at least 
three biological replicates ± SD (error bars) as a function of time (min or hr, as indicated). For 
Cas9-mCherry or mCherry fluorescence levels, background fluorescence of growth media was 
subtracted and the resulting RFU values were normalized to OD600 for each time point. Data are 
displayed as the mean normalized fluorescence (!"#!!"#$%&'()*!"!"" ) of three biological replicates ± 
SD.  
 
Quantification of Cas9 protein and mRNA reporter levels in Listeria  
 Cas9 (WT or dead; Lmo or Spy) reporters (see Figure 2-1A schematic) designed to 
measure protein levels contain a single RBS generating a fused Cas9-mCherry protein. 
Reporters for mRNA levels contain two ribosomal binding sites, one for Cas9 and a second for 
mCherry, generating two separate proteins. All reporters were conjugated into Lmo10403s 
devoid of endogenous cas9 generating strains with the genotype Δcas9, ΔtRNAArg::pPL2oexL-
pHyper-Cas9Reporter. Cells were grown and data collected and processed as in “bacterial 
growth and fluorescence measurements.” Data are shown as the percentage of Cas9 
translation and transcription levels (mCherry fluorescence averaged across 6 hr of logarithmic 
growth) relative to control strains (no prophage (–prophage) or empty vector, as indicated) of at 
least three biological replicates ± SD (error bars). 
 
RT-qPCR of cas9 mRNA levels  
 WT or Cas9-overexpressing Lmo10403s (Δcas9, ΔtRNAArg::pPL2oexL-LmoCas9-
6xHis-FLAG) strains were grown to early (OD600 0.2-0.3) or mid-log (OD600 0.4-0.6) phase and 
1.6 OD600 units of cells were harvested as in “Listeria protein samples.” Cell pellets were 
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resuspended in 100 µl TE buffer supplemented with 0.2 U/µl SUPERase•In RNase Inhibitor 
(Thermo Fisher Scientific) and 5 mg/mL lysozyme, and incubated at 37°C for 10 min. Each 
sample was mixed with solutions pre-heated to 65°C for 15 min: 600 µl hot 1.2X lysis buffer (60 
mM NaOAc, 1.2% SDS, 12 mM EDTA) and 700 µl hot acid-phenol:chloroform pH 4.5 (with IAA, 
125:24:1) (Ambion). After incubating at 65°C for 30 min with shaking at 1500 rpm, followed by 
centrifugation at 12000 g for 15 min at 4°C, 500 µl aqueous phase was recovered for each 
sample. RNA was extracted with neutral phenol:chloroform:isoamyl alcohol (25:24:1) (Sigma) 
three times, precipitated with ethanol, and resuspended in nuclease-free water. Residual DNA 
was removed using the TURBO DNA-free Kit (Invitrogen). RT-qPCR was conducted in technical 
triplicate using the Luna Universal One-Step RT-qPCR Kit (New England Biolabs) according to 
the manufacturer’s instructions in 10 µl reaction volumes and reactions were run on a CFX 
Real-Time PCR Detection System (BioRad). cas9 mRNA and 16srRNA  were analyzed with the 
following primers: cas9-FWD: 5′-ATGCCGCGATAGATGGTTAC-3′ and cas9-REV: 5′-
CGCCTTCGATGTTCTCCAATA-3′; 16s-FWD: 5′-CCTGGTAGTCCACGCCGT-3′ and 16s-REV: 
5′-TGCGTTAGCTGCAGCACTAAG-3′.   
 
Cas9 and anti-CRISPR protein expression and purification 
 N-terminally 6xHis-tagged Acr proteins were expressed from the pET28 vector whereas 
WT SpyCas9 and mutants were expressed from 6xHis-MBP-Cas9 constructs (gifts from 
Jennifer Doudna, UC Berkeley) in E. coli Rosetta (DE3) pLysS cells. Recombinant protein 
expression was induced with 0.25 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 18 °C 
overnight. Cells were harvested by centrifugation and lysed by sonication in buffer A (50 mM 
Tris-HCl pH 7.5, 500 mM NaCl, 0.5 mM DTT, 20 mM imidazole, 5% glycerol) supplemented with 
1 mM PMSF and 0.25 mg/mL lysozyme (Sigma). Cell debris was removed by centrifugation at 
20000 g for 40 min at 4 °C and the lysate incubated with Ni-NTA Agarose Beads (Qiagen). After 
washing, bound proteins were eluted with Buffer A containing 300 mM imidazole and dialyzed 
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overnight into storage buffer (20 mM HEPES-NaOH pH 7.4, 150mM KCl, 10% glycerol, 2mM 
DTT). GST-tagged AcrIIA1 and AcrIIA2b.3 were expressed from pGEX-6P-1 plasmids in E. 
coli BL21 (DE3) cells, lysed in buffer (20 mM HEPES-NaOH pH 7.4, 300 mM KCl and 5 mM 
DTT) supplemented with 1 mM PMSF and 0.25 mg/mL lysozyme, and clarified lysate was 
incubated with Glutathione Agarose Beads (Pierce). After washing, bound proteins were eluted 
using 100 mM Tris-HCl pH 8.5, 150 mM KCl, 15 mM reduced glutathione. The GST tag was 
cleaved with PreScission Protease (Millipore) and proteins were dialyzed overnight in 50 mM 
HEPES-NaOH pH 7.5, 150 mM KCl, 10% glycerol and 2 mM DTT to remove free glutathione. 
Cleaved GST was removed from dialyzed proteins with Glutathione Agarose Beads (Pierce). 
 
in vitro binding of anti-CRISPRs to SpyCas9  
 The binding affinities of anti-CRISPR proteins to SpyCas9 were calculated using 
microscale thermophoresis (MST) on the Monolith NT.115 instrument (NanoTemper 
Technologies GmbH, Munich, Germany). For AcrIIA1/AcrIIA2b.3 with WT or mutant Cas9-gRNA 
complexes, WT and mutant 6xHis-Cas9 proteins were incubated with two-fold molar excess 
gRNA (Integrated DNA Technologies). The substrate proteins AcrIIA1/AcrIIA2b.3 at 0.09 nM to 
3 µM concentrations were incubated with 25 nM RED-tris-NTA-labeled 6xHis-Cas9-gRNA at 
room temperature (RT) for 10 min in MST buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 15 mM 
MgCl2, 0.05% Tween-20). For AcrIIA1/AcrIIA2b.3 with apoCas9, the substrate protein apoCas9 
(QB3 Macrolab) at 0.61 nM to 10 µM concentrations was incubated with 25 nM NT-647-NHS-
labeled AcrIIA1/A2b.3 proteins at RT for 10 min in MST buffer. For AcrIIA1 mutants with WT 
Cas9-gRNA, the substrate protein Cas9-gRNA (QB3 Macrolab) at 15 pM to 0.5 µM 
concentrations was incubated with 25 nM RED-tris-NTA-labeled 6xHis-AcrIIA1 mutant proteins 
at RT for 10 min in MST buffer. Samples were loaded into Monolith NT.115 Capillaries and 
measurements were performed at 25 °C using 40% LED power and medium microscale 
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thermophoresis power. All experiments were repeated three times for each measurement. Data 
analyses were carried out using NanoTemper analysis software. 
 
in vitro pull-downs to verify binding of anti-CRISPRs to SpyCas9 
 5 µg apoCas9 proteins (WT, dead, D10A, or H840A) were incubated with two-fold molar 
excess gRNA at 37°C for 15 min. Cas9-gRNA complexes were incubated with 6-fold molar 
excess AcrIIA1 or AcrIIA2b.3 proteins for 15 min at room temperature in a buffer containing 20 
mM HEPES-NaOH pH 7.5, 150 mM KCl, 10% glycerol, and 1 mM DTT. Samples were then 
incubated with 20 µl Ni-NTA agarose beads (Qiagen) for 15 min at 4°C and washed five times 
with 1x MST buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 10 mM MgCl2, 0.05 % Tween-20). 
Beads were boiled in 1X Laemmli Sample Buffer and proteins were analyzed by SDS-PAGE 
and Bio-Safe Coomassie staining (Biorad). 
 
Limited proteolysis of SpyCas9-AcrIIA1 complex 
 20 µg purified SpyCas9 (QB3 Macrolab) in Apo form or in complex with gRNA (1.1-fold 
molar excess) was incubated with 1.5-fold and 4-fold molar excess AcrIIA1 and AcrIIA2b.3, 
respectively, in protease buffer (10 mM Tris-HCl pH 7.5, 300 mM NaCl) at 25°C for 15 min. 
Alternatively, ApoSpyCas9 was incubated first with AcrIIA protein followed by gRNA addition. 
Proteolysis reactions were performed with 20 ng α-chymotrypsin (sequencing grade, Promega) 
at 25°C and at 0, 10, 30, or 60 min time points, reactions were quenched with 2X SDS Laemmli 
Buffer and boiled for 10 min at 95°C. Samples were analyzed by SDS-PAGE and staining with 
Bio-Safe Coomassie (Bio-Rad). 
 
SpyCas9 protein decay measurements in Listeria 
 Saturated overnight cultures of Lmo10403s strains devoid of endogenous cas9 and 
expressing AcrIIA1 or AcrIIA4 from a tightly regulated rhamnose-inducible promoter (Fieseler et 
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al., 2012) and SpyCas9-mCherry from the constitutively active pHyper promoter (Δcas9, 
ΔtRNAArg::pPL2oexL-pHyper-SpyCas9-mCherry-GyrA_terminator-pRha-AcrIIA) were diluted 
1:100 in fresh LB supplemented with 50 mM glycerol and tetracycline (2 µg /mL) and grown to 
mid-log (OD600 ~0.5). Cultures were then diluted 1:2 in LB containing 50 mM glycerol and 
tetracycline (2 µg /mL) plus 200 mM rhamnose to induce Acr expression or 200 mM glycerol for 
uninduced controls (100 mM final concentration rhamnose or glycerol) in a 96-well microplate 
and treated with gentamicin (5 µg/mL) to inhibit translation or water as a control. Cells were 
grown and data collected and processed as in “bacterial growth and fluorescence 
measurements.” Data are shown as the mean percentage of SpyCas9-mCherry fluorescence 
relative to levels measured at “0 hr” (the beginning of translation inhibition or anti-CRISPR 
induction) of at least three biological replicates ± SD (error bars) as a function of time (min). 
Data were fitted by nonlinear regression to generate best-fit decay curves. 
 
Listeria CRISPRi and self-targeting 
 Single-copy integrating CRISPRi and self-targeting constructs (see Figure 2-1E 
schematics) were designed as follows: pPL2oexL–pHyper-sgRNA [pHELP-spacer] 
GyrATerminator–pRhamnose-Cas9 (Lmo WT or Lmo dead or Spy dead) LambdaTerminator–
pHELP-mCherry-LuxTerminator and conjugated into Lmo10403sɸcureΔcas9 containing 
pLEB579 plasmids expressing the indicated anti-CRISPRs. Overnight cultures were grown in 
LB supplemented with 50 mM glycerol (no induction/repression), 2 µg/mL tetracycline, and 7.5 
µg/mL erythromycin. Cultures were then diluted 1:100 in LB containing 50 mM glycerol and the 
aforementioned antibiotics plus 200 mM rhamnose to induce Cas9 expression (and thus, 
CRISPRi or self-targeting) or 200 mM glycerol for uninduced controls (100 mM final 
concentration rhamnose or glycerol) in a 96-well microplate. Cells were grown and data 
collected and processed as in “bacterial growth and fluorescence measurements.” For self-
targeting, data are displayed as the mean OD600 of at least three biological replicates ± SD 
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(error bars) as a function of time (hr). For CRISPRi, data are shown as the mean percentage 
mCherry expression (mCherry fluorescence averaged across 6 hr of logarithmic growth) relative 
to uninduced controls of at least three biological replicates ± SD (error bars). 
 
Plaque forming unit (PFU) quantification of Listeria phages 
 Phage infections were conducted using the soft agar overlay method: 10 µl phage 
dilution was mixed with 150 µl stationary Listeria culture in 3 mL molten LC top agar 
supplemented with 300 µg/mL Tetrazolium Violet (TCI Chemicals) to generate contrast for 
plaque visualization (Hurst et al., 1994) and poured onto a BHI-agar plate. After 24 hr incubation 
at 30°C, phage plaque-forming units (PFU) were quantified.  
 
Efficiency of plaquing of Listeria phages  
 Efficiency of plaquing (EOP) calculations are a ratio of the number of plaque forming 
units (PFUs) that formed on a Lmo10403sɸcure targeting strain (endogenous cas9 with 
overexpression of the native CRISPR array spacer #1 that targets ɸA006) divided by the 
number of PFUs that formed on a non-targeting strain (Δcas9). Each PFU measurement was 
conducted in biological triplicate and all EOP data is displayed as the mean EOP ± SD (error 
bars).  
 
Construction of self-targeting 10403s::ϕA006 lysogens 
 Lmo10403sΔcas9::ϕA006 isogenic self-targeting lysogens encoding no anti-CRISPR or 
AcrIIA1, AcrIIA4, AcrIIA12 (alone or in combination as indicated) were isolated as in 
“construction of Lmo10403s lysogens.” To prevent self-targeting during strain construction, 
pPL2oexL constructs encoding a tightly regulated rhamnose-inducible LmoCas9 (WT or dead 
as a control) were conjugated into each lysogen. To assess the stability of each lysogen, cells 
were cultured, Cas9 induced, and data displayed as described for the self-targeting strain in 
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“Listeria CRISPRi and self-targeting,” except erythromycin was omitted from LB media. Each 
lysogen stability measurement was performed in biological triplicate.  
 
P. aeruginosa anti-SpyCas9 screening platform  
 The previously described P. aeruginosa anti-SpyCas9 screening platform (Jiang et al., 
2019) and bacteriophage plaque assays (Borges et al., 2018; Jiang et al., 2019) were utilized to 
assay the anti-CRISPR activity of AcrIIA1 homologs and mutants. AcrIIA1 homolog genes were 
synthesized (Twist Bioscience) and cloned into the pMMB67HE-PLac vector. Protein accession 
numbers are listed in Table S1. Site directed mutagenesis by Gibson Assembly was used to 
introduce point mutations into pMMB67HE-PLac-GST-AcrIIA1. The PBAD promoter driving 
chromosomally integrated SpyCas9-3xMyc and pHERD30T-sgRNA was induced with 0.1% 
arabinose and the PLac promoter driving pMMB67HE-AcrIIA with 1 mM IPTG. Expression of 
AcrIIA1 mutants was confirmed by harvesting 1 OD600 unit of cells and resuspending in 200 µl 
1X Laemmli Sample Buffer (Bio-Rad) followed by SDS-PAGE and immunoblotting as described 
above. The fold reductions in phage titer displayed were qualitatively derived by examining at 
least three replicates of each experiment. Plate images were acquired as in “Listeria phage 
titering” and a representative picture is shown.  
 
P. aeruginosa self-targeting and CRISPRi 
 Strains were generated as previously described by Borges et al., 2018 under 
“construction of PAO1::SpyCas9 expression strain,” except the sgRNA was designed to target 
the PAO1 chromosomal phzM gene promoter and was integrated into the bacterial genome 
using the mini-CTX2 vector (Hoang et al., 2000). Cultures were grown overnight in LB 
supplemented with 50 µg/mL gentamicin and 0.1% arabinose to pre-induce anti-CRISPR 
expression and the next day diluted 1:100 with fresh LB containing 50 µg/mL gentamicin, 0.1% 
arabinose, and IPTG (0, 0.01, 0.1 or 1mM to titrate WT or dead SpyCas9-sgRNA expression) in 
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a 96-well microplate (150 µl/well) for self-targeting analysis or glass tubes (3 mL) for CRISPRi. 
Self-targeting experiments were conducted in biological triplicate with cells grown and data 
collected and processed as in “bacterial growth and fluorescence measurements.” For 
CRISPRi, cells were grown for 8-10 hr with continuous shaking after which CRISPRi was 
qualitatively assessed by inspecting the culture pigment. Repression of the phzM gene by 
dCas9 generates a yellow culture whereas inhibition of dCas9 (e.g. by an Acr) allows phzM 
expression and pyocyanin production that generates a green culture. Representative pictures of 
at least three biological replicates are shown.  
 
Co-immunoprecipitation of SpyCas9-3xMyc and GST-AcrIIA  
 Saturated overnight cultures of P. aeruginosa strains were diluted 1:100 in 50 mL of LB 
supplemented with required antibiotics, grown to OD600 0.3-0.4, and induced with 0.3% 
arabinose (SpyCas9-gRNA) and 1mM IPTG (anti-CRISPR). Cells were harvested at OD600 1.8-
2.0 by centrifugation at 6000 g for 10 min at 4°C, flash frozen on dry ice, resuspended in 1 mL 
lysis buffer (50 mM Tris-Cl pH 7.4, 150 mM NaCl, 20 mM MgCl2, 0.5% NP-40, 5% (v/v) glycerol, 
5 mM DTT, 1 mM PMSF), lysed by sonication (20 sec pulse x 4 cycles with cooling between 
cycles), and lysate was clarified by centrifugation at 14 000g for 10 min at 4°C. For input 
samples, 10 µL lysate was mixed with one-third volume 4X Laemmli Sample Buffer. Remaining 
lysate (~1 mL) was mixed with pre-washed Myc-Tag Magnetic Bead Conjugate #5698 (Cell 
Signaling Technology) or Glutathione Magnetic Agarose Beads #78601 (Thermo Fisher 
Scientific) using a lysate to bead slurry volume ratio of 20:1 for Myc or 40:1 for GST. After 
overnight incubation at 4°C with end-over-end rotation, beads were washed five times with 1 mL 
cold wash buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 20 mM MgCl2, 5mM DTT) containing 
decreasing concentrations of NP-40 (0.5%, 0.05%, 0.01%, 0.005%, 0) and glycerol (5%, 0.5%, 
0.05%, 0.005%, 0) on a magnetic stand. Bead-bound proteins were resuspended in 100 µl 
wash buffer without detergent and glycerol. 10 µl bead-bound protein slurry was mixed with 
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one-third volume 4X Laemmli Sample Buffer, boiled for 5 min at 95°C, and samples were 
analyzed by SDS-PAGE using 4-20% Mini-PROTEAN TGX gels (Bio-Rad) and staining with 
Bio-Safe Coomassie (Bio-Rad) or immunoblotting.  
 
Cas9 DNA cleavage assays using immunoprecipitated SpyCas9-3xMyc 
 Reactions were assembled with bead-bound protein slurry and 1.5 nM DNA substrate, 
incubated at 25°C with gentle shaking at 1000 rpm, and at 1, 5, 10, and 30 min time points 
reaction aliquots were mixed with warm Quenching Buffer (50 mM EDTA, 0.02% SDS) and 
boiled at 95°C for 10 min. DNA cleavage products were analyzed by agarose (1%) gel 
electrophoresis and staining with SYBR Safe (Thermo Fisher Scientific). 
 
Cas9 DNA cleavage assays using purified proteins 
 To generate gRNAs, crRNA and tracrRNA were annealed with Nuclease-free Duplex 
Buffer (Integrated DNA Technologies) according to the manufacturer’s instructions. Reactions 
were assembled in 1X MST Buffer (50 mM Tris-Cl pH 7.4, 150 mM NaCl, 20 mM MgCl2, 5 mM 
DTT, 5% glycerol, 0.05% (v/v) Tween-20) with 50 nM SpyCas9 and 625 nM AcrIIA, incubated 
for 5 min on ice, supplemented with 50 nM gRNA, and incubated for an additional 5 min at room 
temperature. Reactions were initiated by adding 2 nM target DNA substrate and at 1, 2, 5 and 
10 min time points reaction aliquots were mixed with warm Quenching Buffer (50mM EDTA, 
0.02% SDS) and boiled at 95°C for 10 min. DNA cleavage products were analyzed by agarose 
(1%) gel electrophoresis and staining with SYBR Safe (Thermo Fisher Scientific). 
 
E. coli phage Mu plaquing assays 
 Plasmids expressing Type II-A, II-B, and II-C Cas9-sgRNA combinations were previously 
described (Garcia et al., 2019, in revision). Cas9 plasmids containing a spacer targeting phage 
Mu and a pCDF-1b plasmid expressing the indicated anti-CRISPR proteins were co-
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transformed into E. coli BB101. After 2 hr of growth in LB at 37°C with continuous shaking, cells 
were treated with 0.01 mM IPTG to induce anti-CRISPR expression, and incubated for an 
additional 3 hr. A mixture of cells and LB top agar (0.7% agar) was poured onto an LB plate 
supplemented with 200 ng/mL aTc, 0.2% arabinose, and 10 mM MgSO4. Ten-fold serial 
dilutions of phage Mu were spotted on top and plates were incubated overnight. Anti-CRISPR 
expression after IPTG induction was analyzed by SDS-PAGE on a 15% Tris-Tricine gel followed 
by Coomassie Blue staining as previously described (Lee et al., 2018). 
 
Inhibition of LivCas9 by anti-CRISPR proteins  
 Plaquing assays were conducted as previously described by Hupfeld et al., 2018. Briefly, 
a pKSV7-derived plasmid expressing AcrIIA1 from the ΦA006 anti-CRISPR promoter or empty 
vector and pLRSR-crRNA plasmids with a spacer against phage ΦP35, ΦA511, or a non-
targeting control were transformed into a Listeria monocytogenes Mack strain containing 
chromosomally-integrated pHelp-LivCas9/tracrRNA or a Listeria ivanovii WSLC 30167 strain 
with an endogenous Type II-A LivCas9 system. A mixture of 200 µl stationary host culture and 4 
mL LC top agar was poured onto an agar plate (LC for ΦP35; 1/2 BHI for ΦA511). Ten-fold 
serial dilutions of phage were spotted on top, plates were incubated at 20°C for ΦP35 and 30°C 
for ΦA511 for one day, and plate images were subsequently acquired.  
 
Generation of human cell expression plasmids 
 Descriptions of plasmids used for expression of sgRNAs (including sgRNA/crRNA target 
sequences), nucleases, and Acr proteins in human cells are available upon request. U6 
promoter sgRNA and crRNA expression plasmids were generated by annealing and ligating 
oligonucleotide duplexes into BsmBI-digested BPK1520, BPK2660, KAC14, KAC27, KAC482, 
KAC32 and BPK4449 for SpyCas9, SauCas9, St1Cas9, St3Cas9, CjeCas9, and NmeCas9, 
respectively. New human cell expression plasmids for CjeCas9, St3Cas9, and NmeCas9 were 
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generated by sub-cloning the nuclease open-reading frames of Addgene plasmids # 89752, 
68337, and 119923, respectively (gifts from Seokjoong Kim, Feng Zhang and Erik Sontheimer) 
into the AgeI and NotI sites of pCAG-CFP (Addgene plasmid 11179; a gift from C. Cepko). 
Human codon optimized Acr constructs containing a C-terminal SV40 nuclear localization signal 
were generated by isothermal assembly of synthetic gene fragments (Twist Biosciences) into 
the NotI and AgeI sites of Addgene plasmid ID 43861. New human expression plasmids 
described in this study have been deposited with Addgene.  
 
Transfection of human cells 
 Approximately 20 hours prior to transfection, HEK 293T cells were seeded at 2x104 
cells/well in 96-well plates. Cells were transfected using 70 ng of nuclease, 30 ng 
sgRNA/crRNA, and 110 ng of anti-CRISPR expression plasmids with 1.25 µl of TransIT-X2 
(Mirus Bio) in 20 µl Opti-MEM. For control conditions containing no acr plasmid, 110 ng of a 
pCMV-EGFP plasmid was utilized as filler DNA; for non-targeting sgRNA/crRNA conditions, 30 
ng of an empty U6 promoter plasmid was used as filler DNA. Genomic DNA was harvested from 
cells 72 hours post-transfection by suspending cells in 100 µl of lysis buffer (20 mM Hepes pH 
7.5, 100 mM KCl, 5 mM MgCl2, 5% glycerol, 25 mM DTT, 0.1% Triton X-100, and 30 ng/ul 
Proteinase K (NEB)), followed by incubation at 65°C for 6 minutes and 98°C for 2 minutes. All 
experiments were performed with at least 3 independent biological replicates.  
 
Assessment of Cas and Acr protein activities in human cells 
 Genome editing efficiencies were determined by next-generation sequencing using a 2-
step PCR-based Illumina library construction method. Briefly, genomic regions were initially 
amplified using Q5 High-Fidelity DNA Polymerase (NEB), ~100 ng of genomic DNA lysate, and 
gene-specific round 1 primers. PCR products were purified using paramagnetic beads as 
previously described (Kleinstiver et al., 2019) and diluted 1:100 prior to the 2nd round of PCR to 
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add Illumina barcodes and adapter sequences using Q5 polymerase. PCR amplicons were 
bead purified, quantified and normalized (Qiagen QIAxcel), and pooled. Final libraries were 
quantified using an Illumina Library qPCR Quantification Kit (KAPA Biosystems) and sequenced 
on a MiSeq sequencer using a 300-cycle v2 kit (Illumina). Genome editing activities were 
determined from the sequencing data using CRISPResso2 (Clement et al., 2019) with 
commands --min_reads_to_use_region 100 and -w 10. 
 
Quantification of prophage induction efficiency  
 Prophages were induced from Lmo10403s::ΦJ0161 lysogens expressing cis-acrIIA1 
from the prophage Acr locus or trans-acrIIA1 from the bacterial host genome by treating with 0.5 
µg/mL mitomycin C as previously described (Estela et al., 1992). After overnight incubation with 
continuous shaking at 30°C, cells were pelleted by centrifugation at 8000 g for 10 min and 
phage-containing supernatants were harvested. To quantify the amount of phage induced from 
each lysogen, phage-containing supernatants were used to infect Lmo10403sΦcure lacking 
cas9 and expressing AcrIIA1NTD (Δcas9;IIA1NTD, to bypass the lytic growth defect of 
ΦJ0161ΔacrIIA1-2) as described in “plaque forming unit (PFU) quantification of Listeria phages” 
and the resulting PFUs were quantified. Data are displayed as the mean PFU/mL after 
prophage induction of four biological replicates ± SD (error bars). 
 
Transcriptional repression of the acr promoter  
 To generate acr promoter transcriptional reporters, the nucleotide sequences (~100-350 
base pairs) upstream of putative acr loci encoding acrIIA1 homologs were synthesized (Twist 
Bioscience) and cloned upstream of an mRFP gene into the pHERD30T vector. Promoter 
sequences are listed in Table S1. Transcriptional reporters were electroporated into P. 
aeruginosa PAO1 strains containing pMMB67HE-AcrIIA1-variants. Saturated overnight cultures 
were diluted 1:10 in LB supplemented with 30 µg/mL gentamicin, 100 µg/mL carbenicillin, and 1 
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mM IPTG to induce AcrIIA1 expression in a 96-well microplate. Cells were grown and data 
collected as in “bacterial growth and fluorescence measurements.” Data are shown as the mean 
percentage RFP repression (RFU values at 960 min for AcrIIA1 mutants and 1170 min for 
homologs, normalized to OD600) in the presence of AcrIIA1 relative to controls lacking AcrIIA1 of 
at least three biological replicates ± SD (error bars).  
 
in vitro binding of AcrIIA1 to the anti-CRISPR promoter  
 The affinities of AcrIIA1 and individual domains for DNA were measured in triplicate 
using MST as described above. Single-stranded complementary oligonucleotides were 
annealed to generate 40 bp acr promoter fragments harboring WT or mutated palindrome. The 
DNA substrate at 0.15 nM to 5 µM concentrations was incubated with 12.5 nM RED-tris-NTA-
labeled AcrIIA1/domains at room temperature for 10 min in 1x buffer (50 mM Tris-HCl pH 7.4, 
150 mM NaCl, 10 mM MgCl2, 0.05 % Tween-20). DNA substrate sequences:  
5’-AACTATTGACTACTACGTATATTCGTAGTATAATGTGAAT-3’ (Wild-type)  
5’-AACTATTGACAACTACGTATATTCGTAGTTTAATGTGAAT-3’ (Terminal Mutations) 
5’-AACTATTGACAACAACCTATATTGGTTGTTTAATGTGAAT-3’ (Six Mutations)  
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 All numerical data, with the exception of the microscale thermophoresis (MST) data, 
were analyzed and plotted using GraphPad Prism 6.0 software. The MST data were analyzed 
using the NanoTemper analysis software (NanoTemper Technologies GmbH) and plotted using 
GraphPad Prism 6.0 software. Statistical parameters are reported in the Figure Legends. 
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Figure 2-1. AcrIIA1 Binds Catalytically Active Cas9 to Trigger its Degradation in Listeria 
 (A and B) Immunoblots detecting FLAG-tagged LmoCas9 protein and a non-specific (ns) protein 
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loading control in Listeria monocytogenes strain 10403s (Lmo10403s) lysogenized with the indicated wild-
type prophages (A, top) or Lmo10403s containing Acr-expressing plasmids (B, top). Dashed lines indicate 
where intervening lanes were removed for clarity (B, top). Representative blots of at least three biological 
replicates are shown (A and B). Schematics of translational and transcriptional reporters used to measure 
Lmo or Spy Cas9 protein and mRNA levels in Lmo10403s (A, middle). Cas9 translational (black bars) and 
transcriptional (gray shaded bars) reporter measurements reflect the mean percentage mCherry relative 
fluorescence units (RFU normalized to OD600) in the indicated lysogens (A, bottom) or strains with Acr-
expressing plasmids (B, bottom) relative to the control strain lacking a prophage (– prophage) (A, bottom) 
or containing an empty vector (B, bottom). Error bars represent the mean ± SD of at least three biological 
replicates. (C) Quantification of the binding affinities (KD; boxed inset) of AcrIIA1 and AcrIIA2b.3 for WT 
SpyCas9-gRNA using microscale thermophoresis. Data shown are representative of three independent 
experiments. (D) SpyCas9-mCherry protein levels post anti-CRISPR induction or translation inhibition. 
Lmo10403s strains expressing SpyCas9-mCherry from the constitutively active pHyper promoter and 
AcrIIA1 or AcrIIA4 from an inducible promoter were grown to mid-logarithmic phase and treated with 100 
mM rhamnose to induce Acr expression (+, thick dashed lines) or 100 mM glycerol as a neutral carbon 
source control (–, thick solid lines) and 5 µg/mL gentamicin (Gent) to inhibit translation (+) or water (–) as 
a control. SpyCas9-mCherry protein measurements reflect the mean percentage fluorescence (RFUs 
normalized to OD600) relative to the SpyCas9-mCherry levels at the time (0 min) translation inhibition was 
initiated (thin solid lines). Error bars (vertical lines) represent the mean ± SD of at least three biological 
replicates. Data were fitted by nonlinear regression to generate best-fit decay curves (thick lines). See 
Figure 2-S1D for additional controls and S1E for data showing tight repression of the pRhamnose 
promoter under non-inducing conditions. (E and F) Anti-CRISPR inhibition of CRISPRi (E) or self-
targeting (F) in Listeria. Lmo10403s strains contain chromosomally-integrated constructs expressing dead 
(E) or catalytically active (F) LmoCas9 from the inducible pRha-promoter and a sgRNA that targets the 
pHelp-promoter driving mCherry expression. For CRISPRi, mCherry expression measurements reflect the 
mean percentage fluorescence (RFU normalized to OD600) in deadCas9-induced cells relative to 
uninduced (–dCas9) controls of three biological replicates ± SD (error bars) (E). For self-targeting, 
bacterial growth was monitored after LmoCas9 induction (orange lines) or no induction (blue lines) and 
data are displayed as the mean OD600 of three biological replicates ± SD (error bars) (F). See Figure 2-
S1F for CRISPRi data with Lmo10403s expressing dead SpyCas9. (G) Translational (black bars) and 
transcriptional (gray shaded bars) reporter levels of catalytically active (left) and dead LmoCas9 (right) in 
Lmo10403s lysogenized with engineered isogenic ΦA006 prophages encoding the indicated anti-
CRISPRs. Measurements were normalized and graphed as in (A, bottom) with error bars representing the 
mean ± SD of at least three biological replicates. (*) Indicates the native orfA RBS (strong) in ΦA006 was 
used for Acr expression. See Figure 2-S1H for equivalent data with Lmo10403s expressing SpyCas9. (H) 
Quantification of the binding affinities (KD; boxed inset) of AcrIIA1 (IIA1, solid lines) and AcrIIA2b.3 (IIA2, 
dashed lines) for catalytically dead (dCas9) and nickase (D10A or H840A) SpyCas9-gRNA complexes 
using microscale thermophoresis. Data shown are representative of three independent experiments.  
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Figure 2-2. AcrIIA1 Inhibits Cas9 DNA Cleavage to Protect Prophages During Lysogeny 
 (A) Left: Representative image of plaquing assays where isogenic ΦA006 phages are titrated in 
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ten-fold serial dilutions (black spots) on a lawn of Lmo10403s (gray background). Dashed lines indicate 
where intervening rows were removed for clarity. Right: Efficiency of plaquing (EOP) of isogenic ΦA006 
phages (expressing the indicated anti-CRISPRs) on Lmo10403s. Plaque forming units (PFUs) were 
quantified on Lmo10403s overexpressing the first spacer in the native CRISPR array that targets ΦA006 
(cas9;pHyper-spacer#1) and normalized to the number of PFUs measured on a non-targeting 
Lmo10403s-derived strain (Δcas9). Data are displayed as the mean EOP of at least three biological 
replicates ± SD (error bars). See Figure 2-S2A for EOP measurements of additional ΦA006 phages. (B) 
Bacterial growth curves of self-targeting Lmo10403s::ΦA006 isogenic lysogens expressing the indicated 
anti-CRISPRs and rhamnose-induced (+) WT or dead LmoCas9. WT LmoCas9 induction (blue lines), but 
not dead LmoCas9 (orange lines) is lethal in an Acr-deficient (Δacr) strain because the Lmo10403s 
CRISPR array contains a spacer targeting the ΦA006 prophage integrated in the bacterial genome. Data 
are displayed as the mean OD600 of at least three biological replicates ± SD (error bars) as a function of 
time (min). (*) Indicates the native orfA RBS (strong) in ΦA006 was used for Acr expression. (C) Left: 
Alignment of AcrIIA1 homolog protein sequences denoting key residues. Right: Phylogenetic tree of the 
protein sequences of AcrIIA1 homologs. See Figure 2-S4D for a complete alignment of the AcrIIA1 
homolog protein sequences. (D and E) Fold reduction in phage titer in response to SpyCas9 targeting of 
a P. aeruginosa DMS3m-like phage in the presence of AcrIIA1 homologs (D) or mutants (E). The percent 
protein sequence identities of each homolog to the full-length (FL) or domains (NTD or CTD) of 
AcrIIA1ΦA006 (IIA1) are listed in (D). The displayed fold reductions in phage titer were qualitatively 
determined by examining three biological replicates of each phage-plaquing experiment. See Figure 2-
S3A for representative pictures of the corresponding phage-plaquing experiments. (F) Immunoblots 
detecting GST-tagged anti-CRISPR proteins that co-immunoprecipitated with Myc-tagged SpyCas9 in a 
P. aeruginosa strain heterologously expressing Type II-A SpyCas9-gRNA and the indicated Acrs. For 
input samples, one-hundredth lysate volume was analyzed to verify tagged protein expression and RNA-
polymerase was used as a loading control. Representative blots of at least three biological replicates are 
shown. See Figure 2-S2F for the reciprocal GST-Acr pulldown. (G) Time courses of SpyCas9 DNA 
cleavage reactions in the presence of the indicated anti-CRISPRs conducted with SpyCas9-gRNA-Acr (or 
no Acr, –) complexes immunoprecipitated from P. aeruginosa. Dashed lines indicate where intervening 
lanes were removed for clarity. Data shown are representative of three independent experiments. See 
Figure 2-S2H for reactions with AcrIIA1 mutants.    
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Figure 2-3. AcrIIA1 is a Broad-Spectrum Cas9 Inhibitor 
 (A) Phylogenetic tree of the protein sequences of Cas9 orthologues: Francisella novicida (Fno), 
Listeria monocytogenes (Lmo), Streptococcus pyogenes (Spy), Staphylococcus aureus (Sau), Listeria 
ivanovii (Liv), Neisseria meningitidis (Nme), Haemophilus parainfluenzae (Hpa), Brackiella oedipodis 
(Boe), Geobacillus stearothermophilus (Geo), Campylobacter jejuni (Cje), Corynebacterium diphtheriae 
(Cdi). (B) Plaquing assays where the E. coli phage Mu is titrated in ten-fold serial dilutions (black spots) 
on lawns of E. coli (gray background) expressing the indicated anti-CRISPR proteins and Type II-A, II-B 
and II-C Cas9-sgRNA combinations programmed to target phage DNA. Representative pictures of at 
least 3 biological replicates are shown. (C) Plaquing assays where the Listeria phage ΦP35 is titrated in 
ten-fold serial dilutions (black spots) on lawns of L. monocytogenes Mack (gray background) expressing 
episomal AcrIIA1 or no Acr (–), chromosomally-integrated LivCas9/tracrRNA, and episomal (pLRSR) 
crRNA that targets ΦP35 phage DNA or a non-targeting control (scr). (D) Gene editing activities of Cas9 
orthologues in human cells in the presence of AcrIIA1 variants and orthologues. AcrIIA4 is a known 
inhibitor of SpyCas9, AcrIIA5 is a broad-spectrum inhibitor (Garcia et al., 2019, in revision), and AcrVA1 
as a known non-inhibiting control for SpyCas9 orthologues. NT, no-sgRNA control condition. Error bars 
indicate SEM for three independent biological replicates. See Figure 2-S3F for editing experiments with 
additional Cas9 orthologues. 
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Figure 2-4. The AcrIIA1 N-terminal Domain Autorepresses the Anti-CRISPR Promoter 
 (A) Left: Representative images of plaquing assays where the indicated Listeria phages were 
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titrated in ten-fold serial dilutions (black spots) on lawns of Lmo10403s (gray background) lacking Cas9 
and encoding AcrIIA1NTD (Δcas9;IIA1NTD) or not (Δcas9). Dashed lines indicate where intervening rows 
were removed for clarity. Right: Cas9-independent replication of isogenic ΦJ0161a or ΦA006 phages in 
Listeria. Plaque forming units (PFUs) were quantified on Lmo10403s lacking cas9 (Δcas9) and 
expressing AcrIIA1NTD (black bars) or not (gray shaded bars). Data are displayed as the mean PFU/mL of 
at least three biological replicates ± SD (error bars). (B) Induction efficiency of ΦJ0161 prophages. 
Prophages were induced with mitomycin C from Lmo10403s::ΦJ0161 lysogens expressing cis-acrIIA1 
from the prophage Acr locus (WT) or not (ΔIIA1-2) and trans-acrIIA1 from the bacterial host genome (+) 
or not (–). Plaque forming units (PFUs) were quantified on Lmo10403s lacking cas9 and expressing 
AcrIIA1NTD (Δcas9;IIA1NTD). Data are displayed as the mean PFU/mL after prophage induction of four 
biological replicates ± SD (error bars). (C) Alignment of the phage anti-CRISPR promoter nucleotide 
sequences denoting the -35 and -10 elements (gray boxes) and conserved palindromic sequence (yellow 
highlight). Terminal palindrome mutations (red letters) were introduced for the binding assay in (D). See 
Figure 2-S4A for a complete alignment of the promoters. (D) Quantification of the binding affinity (KD; 
boxed inset) of AcrIIA1 for the palindromic sequence within the acr promoter using microscale 
thermophoresis. ND indicates no binding detected. Data shown are representative of three independent 
experiments. (E) Expression of RFP transcriptional reporters containing the wild-type (left) or mutated 
(right) ΦA006-Acr-promoter in the presence of AcrIIA1 (IIA1) or each domain (IIA1NTD or IIA1CTD). 
Representative images of three biological replicates are shown. (F and H-I) Repression of RFP 
transcriptional reporters containing the ΦA006-Acr-promoter (black bars in F; gray bars in H) or the 
cognate-AcrIIA1-homolog-promoters (black bars in H and I) by AcrIIA1ΦA006 (mutants in F; wild-type in I) 
or AcrIIA1 homolog (H) proteins. Data are shown as the mean percentage RFP repression in the 
presence of the indicated AcrIIA1 variants relative to controls lacking AcrIIA1 of at least three biological 
replicates ± SD (error bars). The percent protein sequence identities of each homolog to the ΦA006 
AcrIIA1NTD are listed in (H). (G) Immunoblots detecting FLAG-tagged LmoCas9 protein and a non-specific 
(ns) protein loading control in Lmo10403s::ΦJ0161a lysogens or non-lyosgenic strains containing 
plasmids expressing AcrIIA1 (IIA1) or AcrIIA1NTD (IIA1NTD). Dashed lines indicate where intervening lanes 
were removed for clarity. Representative blots of at least three biological replicates are shown.  
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Figure 2-5. AcrIIA1NTD Encoded from a Bacterial Host Displays “anti-anti-CRISPR” Activity 
 (A-B) Plaquing assays where engineered (A) or wild-type (B) L. monocytogenes phages are 
titrated in ten-fold dilutions (black spots) on lawns of L. monocytogenes (gray background) expressing 
anti-CRISPRs from plasmids, LmoCas9 from a strong promoter (pHyper-cas9) or lacking Cas9 (Δcas), 
and the natural CRISPR array containing spacers with complete or partial matches to the DNA of each 
phage. (†) Denotes the absence of a spacer targeting the ΦJ0161a phage. Representative pictures of at 
least 3 biological replicates are shown. Dashed lines indicate where intervening rows were removed for 
clarity (A). Solid lines indicate where separate images are shown. (C) Schematic of bacterial (host) 
AcrIIA1NTD homologs encoded next to Type II-A, I-C, and I-E CRISPR-Cas loci in Lactobacillus delbrueckii 
strains.  
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Figure 2-6. Model for Listeria Phage Anti-CRISPR Functions in Lysogenic & Lytic Growth  
 Listeria temperate phages encode the multifunctional AcrIIA1 (red) for protection against 
CRISPR-Cas in lysogeny (AcrIIA1CTD) and autorepression of anti-CRISPR transcription (AcrIIA1NTD). In 
lysogeny (right), AcrIIA1 binds the Cas9 HNH domain (dark blue in Cas9) to prevent DNA cleavage and 
triggers Cas9 degradation. For replication in lytic growth (left), AcrIIA1 is slow or inefficient, thus a distinct 
coexisting anti-Cas9 protein (like AcrIIA12, orange) is necessary to rapidly inactivate Cas9. 
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Figure 2-S1. AcrIIA1 Binds Cas9 and Stimulates Post-transcriptional Degradation of Lmo and Spy 
Cas9 in Listeria, Related to Figure 2-1 
 (A) Cas9 mRNA levels of Lmo10403s lysogens containing the indicated prophages during early 
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or mid-logarithmic growth as quantified by qRT-PCR. Transcript measurements were conducted in 
technical triplicate and data are shown as the mean 2-ΔCT values normalized to the 16S rRNA 
endogenous control gene ± SD (error bars). (B) Quantification of the binding affinities (KD; boxed inset) of 
AcrIIA1 and AcrIIA2b.3 for Apo SpyCas9 using microscale thermophoresis. ND indicates no binding was 
detected. Data shown are representative of three independent experiments. (C) Limited α-chymotrypsin 
proteolysis of SpyCas9-Acr complexes. Proteolysis of Apo SpyCas9 (set 1) or SpyCas9-gRNA (set 2) 
without anti-CRISPR (–) or in the presence of AcrIIA1 (sets 3, 4, 7; magenta boxes) or AcrIIA2b.3 (sets 5, 
6, 8; purple boxes). For reaction sets 7 and 8, Apo Cas9 was first incubated with anti-CRISPR followed by 
addition of gRNA. (*) Denotes a proteolysis product that appears in all Cas9-gRNA reactions but not Apo 
Cas9 reactions. Dashed lines indicate where intervening lanes were removed for clarity. (D) SpyCas9-
mCherry protein levels post anti-CRISPR induction or translation inhibition. Lmo10403s strains 
expressing SpyCas9-mCherry from the constitutively active pHyper promoter and AcrIIA1 or AcrIIA4 from 
an inducible promoter were grown to mid-logarithmic phase and treated with 100 mM rhamnose to induce 
Acr expression (+, thick dashed lines) or 100 mM glycerol as a neutral carbon source control (–, thick 
solid lines) and 5 µg/mL gentamicin (Gent) to inhibit translation (+) or water (–) as a control. SpyCas9-
mCherry protein measurements reflect the mean percentage fluorescence (RFUs normalized to OD600) 
relative to the SpyCas9-mCherry levels at the time (0 min) translation inhibition was initiated (thin solid 
lines). Error bars (vertical lines) represent the mean ± SD of at least three biological replicates. Data were 
fitted by nonlinear regression to generate best-fit decay curves (thick lines). (E) Lmo or Spy Cas9-
mCherry protein levels (black bars) in Lmo10403s expressing Lmo or Spy Cas9-mCherry from the 
constitutively active pHyper promoter and AcrIIA1 or AcrIIA4 from an inducible promoter. Cas9-mCherry 
measurements reflect the mean percentage mCherry (RFU normalized to OD600) in cells treated with 100 
mM rhamnose (+, induced Acr expression) or 100 mM glycerol (–, non-induced Acr expression), relative 
to a control strain lacking an anti-CRISPR (–Acr). Error bars represent the mean ± SD of at least three 
biological replicates. (F) Anti-CRISPR inhibition of CRISPRi in a Listeria Lmo10403s strain containing a 
chromosomally-integrated construct expressing dead SpyCas9 from the inducible pRha-promoter and a 
sgRNA that targets the pHelp-promoter driving mCherry expression. mCherry expression measurements 
reflect the mean percentage fluorescence (RFU normalized to OD600) in deadCas9-induced cells relative 
to uninduced (–dCas9) controls of three biological replicates ± SD (error bars). (G) Catalytically active 
LmoCas9-mCherry protein levels in Lmo10403s lysogenized with isogenic ΦA006 prophages encoding 
AcrIIA12 alone or in combination with AcrIIA1. LmoCas9-mCherry (black bars) measurements reflect the 
mean percentage mCherry (RFUs normalized to OD600) in the indicated lysogens relative to the control 
strain lacking a prophage (–prophage). Error bars represent the mean ± SD of at least three biological 
replicates. (*) Indicates the native orfA RBS (strong) in ΦA006 was used for Acr expression. (H) 
Translational (black bars) and transcriptional (gray shaded bars) reporter levels of catalytically active and 
dead SpyCas9 in Lmo10403s lysogenized with isogenic ΦA006 prophages encoding the indicated anti-
CRISPRs. Measurements were normalized and graphed as in (G) with error bars representing the mean 
± SD of at least three biological replicates. (*) Indicates the native orfA RBS (strong) in ΦA006 was used 
for Acr expression. (I) Differential interactions of SpyCas9 nickases with AcrIIA1. Partially purified 6xHis-
tagged SpyCas9 (WT, dead, D10A, H840A) proteins (input) were incubated with 2-fold molar excess 
gRNA and subjected to Ni-NTA pull-down in the presence or absence (lanes 1-4; –) 6-fold molar excess 
AcrIIA1 (lanes 5-8) or AcrIIA2b.3 (lanes 10-13). AcrIIA1 (magenta boxes) co-purifies with WT and D10A 
(lanes 6 and 7) but not dead and H840A Cas9-gRNA (lanes 5 and 8). AcrIIA2b.3 (purple boxes) co-
purifies with all four Cas9-gRNA complexes (lanes 10-13). AcrIIA1 and A2b.3 were incubated with Ni-NTA 
beads in the absence of Cas9-gRNA to test for non-specific binding to Ni-NTA beads (lanes 9 and 14).  
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Figure 2-S2. AcrIIA1CTD Mutants Cannot Bind Cas9 or Trigger its Degradation, Related to Fig 2-2 
 (A) Left: Representative image of plaquing assays where isogenic ΦA006 phages are titrated in 
	 111 
ten-fold serial dilutions (black spots) on a lawn of Lmo10403s (gray background). Dashed lines indicate 
where intervening rows were removed for clarity. Right: Efficiency of plaquing (EOP) of isogenic ΦA006 
phages (expressing the indicated anti-CRISPRs) on Lmo10403s. Plaque forming units (PFUs) were 
quantified on Lmo10403s overexpressing the first spacer in the native CRISPR array that targets ΦA006 
(cas9;pHyper-spacer#1) and normalized to the number of PFUs measured on a non-targeting 
Lmo10403s-derived strain (Δcas9). The dashed lines boxing the first 6 phages show a zoomed in view of 
the graph with a distinct x-axis scale. Data are displayed as the mean EOP of at least three biological 
replicates ± SD (error bars). Note that this figure contains the same subset of data displayed in Figure 2-
2A. (B) AcrIIA12 anti-CRISPR activity in a Lmo10403s CRISPRi strain expressing Lmo or Spy deadCas9 
from the inducible pRha-promoter and a sgRNA that targets the pHelp-promoter driving mCherry 
expression. mCherry expression measurements reflect the mean percentage RFU in deadCas9-induced 
cells relative to uninduced (–dCas9) controls of three biological replicates ± SD (error bars). Note that 
AcrIIA12 inhibits Lmo but not Spy deadCas9-based CRISPRi, indicating its specificity against LmoCas9. 
(C) Anti-CRISPR activity in Lmo10403s self-targeting strains containing chromosomally-integrated 
constructs expressing LmoCas9 from the inducible pRha-promoter and a sgRNA that targets the pHelp 
promoter driving mCherry expression. Bacterial growth was monitored after LmoCas9 induction (orange 
lines) or no induction (blue lines) and data are displayed as the mean OD600 of at least three biological 
replicates ± SD (error bars). (D) Translational (black bars) and transcriptional (gray shaded bars) reporter 
levels of catalytically active Lmo and Spy Cas9 in Lmo10403s containing plasmids expressing anti-
CRISPRs. Reporter measurements reflect the mean percentage mCherry (RFU normalized to OD600) in 
the presence of the indicated anti-CRISPRs relative to the control strain containing an empty vector of 
three biological replicates ± SD (error bars). (E) Catalytically active Lmo and Spy Cas9-mCherry protein 
levels in Lmo10403s containing plasmids expressing anti-CRISPRs. Cas9-mCherry measurements (black 
bars) reflect the mean percentage mCherry (RFU normalized to OD600) in the presence of the indicated 
anti-CRISPRs relative to the control strain containing an empty vector of three biological replicates ± SD 
(error bars). (F) Immunoblots detecting 3xMyc-tagged SpyCas9 protein that co-immunoprecipitated with 
GST-tagged anti-CRISPR proteins in a P. aeruginosa strain heterologously expressing the Type II-A 
SpyCas9-gRNA system and the indicated Acrs. For input samples, one-hundredth lysate volume was 
analyzed to verify tagged protein expression and RNA-polymerase was used as a loading control. 
Representative blots of at least three biological replicates are shown. (G) Quantification of the binding 
affinities (KD; boxed inset) of WT and mutant AcrIIA1 proteins with SpyCas9-gRNA using microscale 
thermophoresis. ND indicates no binding detected. Data shown are representative of three independent 
experiments. (H-I) Time courses of SpyCas9 DNA cleavage reactions in the presence of the indicated 
anti-CRISPR proteins conducted with SpyCas9-gRNA-Acr complexes immunoprecipitated from P. 
aeruginosa (H) or recombinant proteins purified from E. coli (I). Where indicated, the reaction with 
SpyCas9-gRNA immunoprecipitated without an Acr (–) was supplemented with recombinant WT AcrIIA1 
protein purified from E. coli (+ pure AcrIIA1) (H). Dashed lines indicate where intervening lanes were 
removed for clarity. Solid lines indicate a separate image. Data shown are representative of three 
independent experiments.    
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Figure 2-S3. AcrIIA1 Inhibition of Cas9 Orthologues in Heterologous Hosts, Related to Fig 2-2–2-3  
 (A) Plaquing assays where the P. aeruginosa DMS3m-like phage is titrated in ten-fold dilutions 
	 113 
(black spots) on a lawn of P. aeruginosa (gray background) expressing the indicated anti-CRISPR 
proteins and Type II-A SpyCas9-sgRNA programmed to target phage DNA. Representative pictures of at 
least 3 biological replicates are shown. (B) Immunoblots detecting GST-tagged AcrIIA1 (mutants or 
individual domains) proteins, Myc-tagged SpyCas9 protein, and RNA-polymerase as a protein loading 
control in a P. aeruginosa strain heterologously expressing the Type II-A SpyCas9-gRNA system and the 
indicated Acrs. (*) Denotes GST degradation products derived from GST-tagged Acr proteins. AcrIIA1 
mutants that failed to express were not analyzed further. (C) Anti-CRISPR activity in P. aeruginosa self-
targeting (left) and CRISPRi (right) strains containing plasmids expressing anti-CRISPRs and 
chromosomally-integrated SpyCas9-sgRNA programmed to target the phZM gene promoter. For self 
targeting, SpyCas9 expression from the inducible pLAC-promoter was titrated using the indicated IPTG 
concentrations (mM) and bacterial growth curves display the mean OD600 of at least three biological 
replicates ± SD (error bars) measured over time (left). CRISPRi was qualitatively assessed by inspecting 
the culture pigment. Transcriptional repression of the phzM gene by dCas9 generates a yellow culture 
whereas inhibition of dCas9 (e.g. by an Acr) allows phzM expression and pyocyanin production that 
generates a green culture. Representative pictures of at least three biological replicates are shown (right). 
(D) SDS-PAGE and Coomassie Blue staining analysis of AcrIIA1 expression after IPTG induction in E. 
coli strains containing the indicated Cas9 orthologues. (E) Plaquing assays where the Listeria phage 
ΦA511 is titrated in ten-fold serial dilutions (black spots) on lawns of the Listeria ivanovii WSLC 30167 
(gray background) strain with an endogenous Type II-A LivCas9 system or lacking this system (Δcas), 
plasmid-expressed AcrIIA1 or no Acr (–), and crRNA that targets ΦA511 phage DNA or a non-targeting 
control (–) expressed from the pLRSR plasmid. (F) Gene editing activities of Cas9 orthologues in human 
cells in the presence of AcrIIA1 variants and orthologues. AcrIIA4 is a known selective inhibitor of 
SpyCas9, AcrIIA5 is a broad-spectrum inhibitor (Garcia et al., 2019, in revision), and AcrVA1 as a known 
non-inhibiting control for SpyCas9 orthologues. NT, no-sgRNA control condition. Error bars indicate SEM 
for three independent biological replicates. 
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Figure 2-S4. Acr Promoters in Mobile Genetic Elements Across the Firmicutes Phylum are 
Autoregulated by AcrIIA1 Homologs, Related to Figures 2-2 and 2-4 
 (A) Alignment of the phage anti-CRISPR promoter nucleotide sequences denoting the -35 and -
10 elements and ribosomal binding site (RBS) (gray boxes) and conserved palindromic sequence (yellow 
highlight). (B) Quantification of DNA binding abilities (KD; boxed inset) of full-length AcrIIA1 and each 
domain (AcrIIA1NTD and AcrIIA1CTD) using microscale thermophoresis. Data shown are representative of 
three independent experiments. ND indicates no binding detected. (C) Expression strength of the AcrIIA1 
homolog promoters. Data are shown as the mean RFP expression (RFU normalized to OD600) driven by 
each AcrIIA1 homolog promoter of at least three biological replicates ± SD (error bars). (D) Alignment of 
AcrIIA1 homolog protein sequences. 
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Figure 2-S5. Bacterial expression of AcrIIA1NTD blocks phage anti-CRISPR deployment, Related to 
Figure 2-5  
 (A) Plaquing assays where wild-type L. monocytogenes phages are titrated in ten-fold dilutions 
(black spots) on lawns of L. monocytogenes (gray background) containing single-copy integrated 
constructs expressing AcrIIA1 or AcrIIA1NTD from the ΦA006 anti-CRISPR promoter (pA006), LmoCas9 
from a constitutive promoter (pHyper-Cas9), and the natural CRISPR array containing spacers with 
complete or partial matches to the DNA of each phage. (†) Denotes the absence of a spacer targeting the 
virulent phage ΦP35. Representative pictures of at least 3 biological replicates are shown. 
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Table 2-S1. AcrIIA1 homolog protein accession numbers and associated promoter 
sequences 
 
Strains Containing  
AcrIIA1 Homologs 
Designated 
Homolog Name 
Protein  
Accession # Associated Promoter Sequence (5’ to 3’) 
Listeria monocytogenes 
J0161 
LmoɸA006/ 
ɸJ0161 WP_003722518.1 
tttacttcacctcttgacaacattatacgaacaaacgttcttaaaatcaagtgttaaaaagtgtt
gtattacataaaaatctatgtaataatattcacatgaacgattttcgttcattatttcattcaactatt
agctgtttgacatcccgttttacatctgaatataacagcaacctcgaatttttcggggtatttttttat
attgaaaataaatttaataaaactattgactactacggcgattcgtagtatactatgtatatagt
aaagaaaacaattgaaaaggatggatgacaaa 
Listeria monocytogenes 
strain LMO10 LMO10 KUG37233.1 
ttttgttgacgctttcacaaagacatgttattatatattcaagaacttaataagttctagcgctgttt
cggcgcgttttaattacgcattgtgcaatgtaaatttctatgtatttaattttatttagcacgaaaag
aagctacaaattttaactacttactatgaaatgtaaggaaaaaaacatcagacttcggtttgat
gtttttttactgtaaaaaaattaatccaataaaaaccattgactactacgattattcgtagtataat
atgtatatagtaaaggaacgggaggaaaataca 
Listeria monocytogenes 
strain FRRB 2887 LmoFRRB2887 WP_085696370.1 
aataaaaagtaacctgtttttctatagattgctttttatcatatatatagaagaaagccgctttttatt
agattataattgatgttttttgatttatatttcactccctgtgcaaataacgatatagtagcaacctc
gaacttttttgttcggggtatttttttgaaattaatttataaaaacacttgactactacgaatttacgt
agtatactttaaatatagtaaagataacgaaacggaggaacttaaaa 
Listeria monocytogenes 
isolate 22B09 Lmo22B09 WP_077316628.1 
ttttatcagttattttaaaaaaggttatctttcgtaaaacgcctatatgtagccgttttatagatagat
agccttttttctttctgtttgaatcggtatattccagaaaagttttgccacgaatttgccacaaaattt
gccgttgaataattctttataaatatagtagtgcctcggactttatggttcggggtatttttttgaaat
taatttataaaaacacttgactactacgaatttacgtagtatactttaaatatagtaaagataac
gaaacggaggaacttaaaa 
Listeria seeligeri  
FSL S4-171 Listeria seeligeri EFS02359.1 
ttgaaatgatgtacacgaacttgttcgctttagtagaaatagaccctcgcgacgaaaaaaga
tattacttttccgacttaactcgtgatgaagtatttacaatgctgcaaaatatcaaaaataaata
atgaatatagttgactaatacgaaaaatcgtagtatactgtgtatatagtaaagaaacggga
ggagcttaaaa 
Enterococcus rivorum  
strain LMG 258993 E. rivorum WP_069698591.1 
tgttcgtatttaggactataccgtaaaatttcgtacaactgatctggagataatcgcttattaaat
gagaagattataataataaaaattgaaaacgttgatttaacagagttttcaaaaaaatataag
aaaatataccgtaaaatttcgttccactgatacgtggaccccaaaaattgaagtaaattgag
cgaaactcttgatttcttccgatttcggaagtataatagtgttataaggttgggataaggaaata
gcacttccgcttaatcttaaataaattaaaagaggatgaatgaa 
Listeria monocytogenes 
CFSAN026587 plasmid Lmo plasmid WP_061665673.1 
aacttacaatagtataggagcgttgctaatcattgctgtatgcttaaagaagtgcagatttaaa
attagatatctttataactttattaaattatagttgactattaaattataatttagtataataaaggtat
agagataagacataaaaatagaacaaatgaggtgcaatgac 
Leuconostoc gelidum 
subsp. gasicomitatum 
KG16-1 
Leu gelidum CUR63869.1 
tattattttccctctaaaataatagtacgtattaaacaagatgaactcttaatgttatttgccattag
atataactgtaacacaatcgtaacattaatctattgcacactgcttaattaagcggtatacttaa
ttcaaggttaaggaagaggtaaacgac 
Lactobacillus parabuchneri 
strain FAM23166 Lac parabuchneri WP_084975236.1 
aaccccttgtatagcataaaggttgcaatcctgccgagtgcataatcgcggtaaatcatcgat
tccgcatattcgttaatgtgatgcctccagtctctttagatgagagattggaggcattttttgcttttt
aaaaaccgatgttttatattgcatacttcgctgtaacgtagtaatattttaaaacatgaagttgcg
acacacagttaacttcgttattatttaacagtaaattcatggaggaaaaaca 
Enterococcus faecalis 
strain plasmid Efsorialis-p2 E. faecalis WP_002401838.1 
ctaccataagttactgatagaaaagaaccaacagagtatgccttgttggttcttttctttgtccag
ttgttaccaggtcagtagtaggacattcaaattgggcatacgtcatttgtgttaattttgagtacg
ctttaaatttacatgtaatgaataaagtaatgggtattcgttttccactaactggccaaacagat
agataggtgaagaacaaatttaacgcaaatggtaatgattgtgtttacatttaccttatatgtga
tataatataagtgtaatcaaagaagcctactcttgaaaattcaagaataggcaggtcgctaa
acctctttgattataccatatatcaaaggaagaaggaatgaaa 
Listeria monocytogenes 
SLCC2540, serotype 3b Lmo orfD WP_012951927.1 
acaaagaacatgcaaattatttaaaaagccgttcagctgcgcgatcttttattaagaaaaaa
gccactttagaagacttggaagaactagaaattgcagtaaagcaaagaaaaactgaaata
atttcattagacaatagccctgaatgaaaaatttcggggcatttttttatttttataatcaaatataa
ttgactaatcaaatatatcgtgttatactatatatagtaaagaaacgggaggcgtacata 
Lactobacillus delbrueckii 
strains L. delbrueckii OOV09772.1 
not applicable; AcrIIA1NTD homolog in core bacterial 
genomes found next to Type I-E, I-C, or II-A CRISPR-Cas 
systems  
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